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ABBREVIATIONS
(GMCSF) Granulocytes colony stimulating factor
(EMT) Epithelial to mesenchymal transition
(CCLS) Chemokine C-C motif ligand S
(CCL2) Chemokine C-C motif ligand 2
(iNOS) Inducible nitric oxide synthase
(EMDR) Enviromental mediated drug resistance
(CSFE) S,6-carboxy fluorescein diacetate succinimidyl ester
(Doxil) Doxorubicin HcI Liposome Injection
(H&E) Haematoxylin and Eosin
(M I) Pro-inflammatory macrophages, M I phenotype
(M2) Pro-tumor macrophages, M2 phenotype
(Mac I) Macrophage antigen I
(MDSCs) Myeloid-derived suppressor cells
(MCP-I) Monocyte chemotactic protein-I
(NI) Pro-inflammatory neutrophils, NI phenotype
(N2) Pro-tumor neutrophils, N2 phenotype
(N-BPs) Nitrogen-containing bisphosphonates
(NF K. b) Nuclear factor- K. b
(TGF- B) Recombinant transforming growth factor-beta
(E-CAD) E-Cadherin
(N-Cadh) N-Cadherin
(ECM) extracellular matrix
(LOX) Lysil Oxydase
(SPARC) secreted protein acid and rich in cysteine
(LAIRs) leukocytes-associated Ig-like receptors
(AAMs) alternatively activated macrophages
(Treg) T regulatory cells
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(M-CSF) macrophage colony-stimulating factor
(GlTR) glucocorticoid-induced TNF receptor family-related gene
(nTreg) natural Treg (nTreg)
(iTreg) induced (or adaptive) Treg
(G-MOSC) granulocytic MOSCs
(M-MOSC) monocytic MOSCs
(BCL-XL) B-ceJllymphoma XL
(CDK4) cyc1in-dependent kinase 4
(PDGF) platelet-derived growth factor
(VEGF) vascular endothelial growth factor
(ATRA) all-trans retinoic acid
(MMP-9) matrix metaJloproteinase-9
(PMNs) Polymorphonuclear lymphocytes
(GEP) Gene Expression Profile analysis
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ABSTRACT
The matricellular protein SPARC (secreted protein acidic and rich in cysteine) is a
master regulator of tissue stroma; it is expressed during tissue remodeling and repair
and its impaired regulation has a role in fibrotic responses, in determining the
composition of the tumor-associated stroma and, less expected, in regulating the
immune response. The complexity of studying SPARC in cancer stems from its
concomitant or alternative expression in tumor and/or stroma cells depending on the
tumor histotypes. Extracellular matrix (ECM) gene profile of human breast
carcinomas correlates SPARC expression with prognosis and response to therapy. In
particular, a subgroup of breast tumors can be identified based on ECM gene
signature headed by SPARC that correlates with tumor grade, bad prognosis and poor
response to therapy. Epithelial to mesenchymal transition (EMT) has been associated
to drug resistance and SPARC has been implicated in EMT. Nevertheless the source
of SPARC and its path toward EMT and the associated drug resistance have not been
identified yet. I have used a well-defined model of transgenic mouse mammary
carcinoma expressing the mutated rat oncogene c-erB2 (HER-2/neu), under the
mouse mammary tumor virus promoter, backcrossed with Spare" mice to establish
mammary carcinoma cell lines devoid of SPARC expression, in which SPARC can be
restored by retroviral gene transduction. With this isogenic cell lines I have been able
to show that SPARC expression in tumor cells induces EMT only in vivo, indicating
that EMT is a microenvironmental and not a cell autonomous process. Moreover,
SPARC expressing tumors became resistant to treatment with Doxil (Doxil, a
pegylated form of Doxorubicin). Investigating the environmental players responsible
of EMT in SPARC transduced tumors, I found that myeloid cells and particularly the
so called myeloid derived suppressor cells (MDSC) have a role in EMT and drug
resistance depending on SPARC. SPARC does not change the number or ratio
between the Ly6Ghigh and the Ly6G1ow fractions of CD11b MDSC rather it determines
the immunosuppressive phenotype of recruited myeloid cells. The data show that
SPARC-forced expression increased the activation of pro-tumoral (CCL2, CeLS) and
immunosuppressive (Argl, NOS2, Cox-2) genes in monocyte-MDSC (the Ly6G1ow
fraction). Furthermore, the role of myeloid cells recruited in Doxil resistance and
EMT has been proven adding bisphosphonate to Doxil during treatment.
Bisphosphonates have been shown to inhibit induction and function of myeloid
suppressor cells. Indeed, Bisphosphonates addition reverted EMT, the
immunosuppressive phenotype of myeloid cells and rendered SPARC-producing
tumors sensitive to Doxil administration.
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1. GENERAL INTRODUCTION
1.1 The Tumor Microenvironment
1.1.1 Tile tumor stroma
For decades, pathologists have recognized that the stroma surrounding tumours
is, in many cases altered with changes in cellular and ECM composition 1. Over the
years descriptive studies have verified that gene expression is altered in the carcinoma
-associated stroma and suggested it would be reasonable to look at the role of the
tumour stroma in tumorigenesis and to find out new possible targets for cancer therapy
within the tumour microenvironment 2. The basic concept of this cancer perspective is
that carcinomas (and other tumours) do not exist in isolation but instead emerge and
exhibit a range of behaviors regulated by host cells comprising the tumour stroma.
During tumor progression and metastasis an active cross-talk occurs between tumor
cells and their associated stroma, mainly mediated by cell-to-cell contact or paracrine
cytokines and growth factors; signaling that is reminiscent of the communication
between epithelial and mesenchymal cells during embryonic development. As a result
of these interchanges, tumor stroma undergoes a number of morphological changes
(desmoplasia) allowing tumor growth, invasion and metastasis. It is now widely
accepted that tumor cells lacking the intrinsic ability to initiate angiogenesis,
proliferate, resist apoptosis or invade and metastasize can acquire such properties via
their interaction with the microenvironment. Stroma can also limit the influx of
inflammatory cells, or the access of therapeutics to the tumor, alter drug metabolism
and contribute to the development of drug resistance. Areas of tumor-host interaction
are populated by different types of extracellular matrix (ECM) components and stroma
cells all contributing to the final tumor outcome. Among the identified cells are
fibroblasts, epithelial cells, adipocytes and vascular cells. The ECM is a network of
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fibrous structural proteins, such as collagens and fibronectin, which are embedded in a
viscoelastic gel of glycosaminoglycans, proteoglycans and glycoproteins. Fibrous
proteins not only form the scaffold of the stroma and provide tensile strength, but also
represent channels for communication and movement of cells and might exert a
regulatory function on a variety of cells.
1.1.2 Matrix stiffness regulates tumor growth and progression
Although tightly controlled during embryonic development and organ
homeostasis, ECM deposition is commonly deregulated and disorganized in diseases
such as cancer. Abnormal ECM affects cancer progression by directly promoting
cellular transformation and metastasis. An increase in collagen deposition or ECM
stiffness, alone or in combination, up-regulates integrin signaling and can promote cell
survival and proliferation 3,4. In mouse models Lenvental et al. demonstrated that an
increase in collagen deposition or ECM stiffness resulting from overproduction of
lysyl oxidase (LOX), an enzyme that cross-links collagen fibers and other ECM
components, promotes focal adhesion assembly, ERK and PI3 kinase signaling and
facilitates Neu-mediated oncogenic transformation s. In addition, mammary fad pad
conditioned by fibroblasts constitutively expressing LOX promoted the transformation
and invasion of pre-malignant mammary cell lines. The regulatory role of the ECM is
not restricted solely to tumor cells, but also extends to immune cells. Inflammation,
characterized by massive influx of immune cells, plays a causative role in cancer
development. Although their initial function is supposed to suppress tumor growth, at
later stages immune cells, including macrophages, are often altered and recruited by
tumor cells to promote cancer. In this context, abnormal ECM might affect many
aspects of immune cell behaviors, including infiltration, differentiation, and functional
activation. For example, mice lacking the ECM glycoprotein SPARC (secreted protein
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acidic and rich in cysteine) have an increased number of macrophages in tumors,
suggesting that the ECM can influence the number of immune cells. One way the ECM
affects the immune cells is by regulating cell proliferation. The ECM also regulates the
activation of immune cells. For example, increased ECM stiffness can promote
integrin-mediated adhesion complex assembly and activate T cells. Although collagen
type I promotes infiltration of immune cells, it inhibits the ability of macrophages to
kill cancer cells by blocking polarization and, thus, activation of macrophages. These
findings highlight the complex ways in which ECM deregulation may affect behaviors
of different groups of immune cells. The inhibitory effect of collagen I on immune
cells is likely mediated by its binding with the leukocyte-associated Ig-like receptors
(LAIRs), which are expressed at the surface of most immune cells. At present, it is not
clear whether LAIRs and integrins cooperate; however, the activation of LAIRs is a
plausible mechanism whereby high levels of tumor collagen can attenuate the
otherwise tumor-suppressive function of immune cells.
1.1.3 The immune microenvironment of solid tumors.
In homeostatic tissue, resident immune cells serve as sentinels that safeguard
tissue and organ integrity. Following acute damage (e.g., infiltration/infection by
pathogens or physical trauma), one activity of resident leukocytes is to limit tissue
damage while engaging tissue repair programs (e.g., activation of stromal fibroblasts
and vasculature for matrix resynthesis and angiogenesis, respectively, and recruitment
of leukocytes from peripheral blood to remove damaged cells and debris) and facilitate
re-epithelialization, all without inducing autoimmunity. Following resolution of wound
responses, tissue damage is (hopefully) minimal and homeostatic maintenance
programs return such that organ physiology is unperturbed. In cancer, immune cells
play dual roles with potential to either eliminate or promote malignancy. Premalignant
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tissues contain proliferating cells harboring genomic damage (e.g., "initiated" cells)
that typically activate critical proliferation/survival pathways. In these tissues, chronic
engagement/activation of immune cells, stromal fibroblasts, and vascular and
mesenchymal support cells together fosters survival of "initiated" cells, culminating in
tissue expansion and development of premalignant lesions via a process reminiscent of
typical "inflammatory-type" responses observed in tissues responding to acute
damage/trauma 6, When these chronic inflammatory-type events are sustained,
neoplastic progression can ensue. Unresolved chronic immune responses thus resemble
the resolution phase of wound healing, where the tumor microenvironment contains
significant infiltrations of cells with immunosuppressive activity akin to a wound
failing to heal 6, Consistent with this, studies evaluating leukocyte complexity by flow
cytometry in human (and murine) tumors have identified multiple immune cell types
that variably contain immunosuppressive activity and, among them, three types of
leukocytes in particular have emerged as playing significant roles in suppressing anti-
tumor
,
Immune responses: macrophages, particularly alternatively activated
macrophages (AAMs); regulatory T cells (Treg) and immature myeloid cells.
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Infiltrating immune cells Subtype
Pro-angiogenic. pro-invasive,
pro-metastatic: suppress
CTL and NK/T cells
Cancer cell killing. direct
and via helping CTL.
Fibers deposition regulates
ECM stiffness and tumor
progression. immune cells
polarization throught
binding with immune
modulatory molecules.
Pro-angiogenic; pro-
invasive; support CSCs.
Fig.1.1.1 Schematic representation of the tumor stroma.
CD45 staining (violet box) on OCT tumor sections isolated from a transplantable model of
breast tumor identified the immune components of tumor stroma in which different immune
cells subtypes are recognized for antagonistic functions highlighted in gray; (blue box)
structural components of tumor stroma, here IHC staining of Col IV and Vimentin of breast
tumor sections; (green box) stromal cells like CAFs and MSC, herein stained with a-SMA and
a-CD146 mAbs.
1.1.3.1 Tumor-associated macrophages
Derived from hematopoietic precursor cells, macrophages have advanced
plasticity and key functions in both immune response and tissue homeostasis and
integrity. Macrophage activities result from their state of activation as function of the
predominant cytokine milieu characterizing the microenvironment in which they are
recruited. A common simplification classifies macrophages as Ml or M2 when
referring to classical1y activated or alternatively activated macrophages, respectively 7.
MI macrophages are pro-inflammatory, producing high levels of IL-12, IFNy and
TNFu, whereas M2 macrophages are anti-inflammatory, producing high levels of IL-
16
10, low IL-12 and TNF(l 8. In addition to this established classification, macrophages
can be classified according to the their various states of activation (at least three) that
are not mutually exclusive and can be blended to generate different functional
outcomes 9. Such functional classification includes: 1. Classically activated
macrophages, producing high levels of IL-12 and low levels of IL-l 0; 2. Regulatory
macrophages, producing high levels of IL-IQ and low levels of IL-12; 3. Wound
healing macrophages, differentiated by IL4 and capable to deposit ECM proteins. In
tumors, virtually all types of macrophages can coexist and the predominant population
can either promote or halt tumor growth. The original hint about the tumor-growth
supporting role of macrophages came from the early description of a prominent
lymphoreticolar infiltrate in carcinomas localized in the tumor stroma that did not
show any cytotoxic activity, not even against the nearest tumor cells. From an
immunological point of view, these macrophages were called anergic. Nowadays, they
are characterized as "homeostatic" macrophages that, recruited by the tumor, help to
orchestrate the tumor microenvironment depositing ECM, releasing VEGF and MMPs
and contributing to local immunosuppression. Large part of our knowledge on tumor-
associated macrophages comes from studies in mice lacking macrophage- colony
stimulating factor (M-CSF) or granulocyte macrophages-colony stimulating factor
(GM-CSF). Colony-stimulating factors were first described for the ability to stimulate
the formation of colonies from bone marrow (BM) precursors in vitro. The effects of
M-CSF on macrophages and of GM-CSF on monocytes, granulocytes and dendritic
cells (DCs) include: proliferation, survival, differentiation and functional activation'",
Among CSFs, M-CSF is the most potent macrophage differentiation factor; M-CSF
KO mice show general paucity of macrophages in various tissues that impacts on
tissue homeostasis, for example impairing mammary gland development'v''',
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Homeostatic macrophages resemble M2-polarized macrophages. Accordingly,
macrophages differentiated from BM in the presence of M-CSF release IL-IO and
MCP-l after LPS stimulation and show a more M2-polarized phenotype, whereas
macrophages obtained in the presence of GM-CSF respond to LPS by releasing pro-
inflammatory cytokines, thereby showing an MI-activation. Monocytes differentiate
into macrophages under the influence of the cytokines present in the microenvironment
while maintaining some plasticity. For example, it is possible to induce tumor
regression re-directing their polarization from M2 to Ml by local delivery of TLR-9
ligand combined with a mAb to IL-IOR 13 or by enriching, the tumor
microenvironment with macrophages unable to activate NF-kB 14. Contrary to the
tumoral setting, liver injury and repair require two distinct subpopulation of
macrophages one monocyte derived and the other derived from a nonhematogenous
source, likely Kupffer cells 15. Although the injury phase is characterized by high
TNFa and little IL-to and the recovery phase by little TNFa and IL-IO, it is
undetermined whether the functional distinction is related to the macrophage origin 16.
Thus, plasticity seems relevant at least in tumors. The potential plasticity of
macrophages adapting their activity to the different phase of tumor development can be
summarized as follow: 1. Initiate tumorigenesis by inducing inflammation and
epithelial cell transformation (Ml-macrophages). Inflammatory macrophages can also
have a role in metastasis. 2. Sustain tumor growth and progression. Participate in TM
architecture through production of ECM proteins and VEGFs (wound healing
macrophages, M2-like macrophages not necessarily expressing predominantly IL-l 0 or
IL-12). Contribute to an immunosuppressive environment by producing high level of
IL-to and low level of TNFa and IL-12 (M2-like, regulatory macrophages). 3. Halt
TM growth or mediate tumor rejection if properly stimulated or redirected to undergo
18
classical activation. The most compelling data showing macrophage-assisted tumor
growth and progression came from studies on VEGF and studies using M-CSF KO
(op/op mice) that, in addition to general macrophages paucity, show defects in tissue
development. VEGF is one of the most important factors involved in tumor
angiogenesis and stroma reaction. Tumors have been defined as "wounds that never
heal" because of their persistent VEGF production'", but macrophages can produce this
cytokine as well as respond to it 18. In breast cancer, genetic depletion of macrophages
in Polyoma Middle T oncoprotein (PyMT)-induced mammary tumors (PyMT plus
op/op, double mutants) and the consequent absence of macrophages-produced VEGF
delayed tumor progression because of reduced tumor angiogenesis, leukocyte
infiltration and tumor-cell invasion. Such defects were caused by the absence of M-
CSF, hence, of macrophages, and were reverted by the transgenic expression of
VEGF-A directly into the tumors 19. In the tumor microenvironment, M2-like
macrophages are likely to sense the cytokines released in the tumor microenvironment
such as IL-I0 and can further polarize toward an M2 regulatory phenotype. In such
phenotype, tumor-associated macrophages (TAMs) release high levels of IL-to that
contribute to the maintenance of the immunosuppressive phenotype of tumors. In this
condition, TAMs are not able to present tumor-associated antigens (TAAs), which
partly explains why immunotherapies with a single TAA or based on tumor cell
transduction with a single cytokine capable of inducing macrophages recruitment
failed or were restricted to particular conditions.
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1.1.3.1.1 Macrophage role in tumor rejection
Macrophages plasticity opens up the interesting possibility of functionally
reverting M2 macrophages fostering tumor growth into M1 macrophages that are
capable of tumor rejection. Gene transduction of solid tumor cells with a gene
encoding for a chemokine (CCL16) recruits new macrophages that exclusively display
an M2 phenotype. The addition of a TLR-9 agonist (CpG) and inhibition of IL-I 0
(mAb to IL-IOR) change the TAM phenotype to MI and tumor debulking is quick
(less than 24h) and massive, largely via a TNFa-dependent mechanism 13.20. Also,
TAMs in the microenvironment of ovarian carcinoma can be redirected either by
specifically blocking the NF-kB activity that, in this tumor type, contributes to the
immunosuppressive phenotype of cancer, or by the use of Smac-mimetic compounds 14
21, In tumor-bearing mice, the adoptive transfer of these re-directed macrophages
impairs tumor growth and metastasis 14,
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Fig.J.1.3.1 Plasticity of tumor-associated macrophages, from tumor initiation to
tumor rejection.
M2-like Macrophages ROS activity are associated to cells damage in colon carcinogenesis;
M2- alternative macrophages phenotype are challenging by 1L41IL13 and associated to wound
healing. 1L-1O is associated to tumor immunosuppressive M2 macrophages. The image was
adapted/ram Sangaletti S. and MP Colombo AACR Educ. Book. 2008.
1.1.3.2 The biology of regulatory T cells
The first evidence about the existence of Treg was provided, at the beginning of
1970s, by Gershon and colleagues, who called them suppressive T cells 22,23. Few years
later, using mouse tumor models, it was also proven that these suppressive
lymphocytes promote tumor growth 24, Despite the immunological relevance of these
studies, the field of Treg was abandoned for decades, up to 1995, when Sakaguchi and
collaborators demonstrated that self-tolerance is regulated and maintained by
suppressive T cells expressing the alpha-chain of interleukin 2 (lL-2) receptor (CD25),
They showed that the inoculation of CD4+CD25" non-suppressive lymphocytes in
BALB/c nu/nu mice induces the development of autoimmune pathologies, and that the
reconstitution of the suppressive CD4+CD25+population prevents the development of
those diseases. Since this discovery, numerous scientists focused their attention on this
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particular T cell subset, investigating their roles in both physiological and pathological
conditions. IL-2Ra (CD25), with IL-2R~ (CD122) and yc (CD132), constitute the IL-2
receptor (IL-2R) 25. The assemblage ofIL-2R is a cascade process: at the beginning IL-
2 binds to the CD25 subunit and this interaction causes a conformational modification
in IL-2 structure, which allows the binding ofCD122 to IL-2. Finally the yc subunit is
included in the structure and renders itmore stable 25. IL-2 signaling is crucial for Treg
development and, consequently, for peripheral homeostasis: in fact, mice with
impaired IL-2/IL2R axis are affected by lethal autoimmune diseases mainly due to
alteration in regulatory lymphocytes 25-27. The intracellular signaling of IL-2 is
primarily mediated by signal transducer and activator of transcription 5 (StatS) 28. It
was also demonstrated that Treg cells constitutively express basal level of CD40L, so
that, via CD40, DC (Dentritic Cells) is stimulated to produce an amount of IL-2
sufficient to ensure their survival. The relevance of CD40/CD40L axis in Treg cells
biology was clearly observed in CD40 KO mice, in which Treg cells have lower
proliferative and survival potential 29. At the beginning of the 2 l" century, the
discovery that the transcription factor forkhead box P3 (Foxp3), located on X
chromosome, was mutated both in scurfy mice and in humans with immune
dysregulation, polyendocrinopathy, enteropathy, and X-linked syndrome (IPEX) 30,31
led to the idea that this transcriptor factor could be involved in Treg development. In
fact two years later Foxp3 was identified as the master regulator for Treg
differentiation and functions 32, It was demonstrated not only that in absence of Foxp3
the development of Treg is impaired, but also that the ectopic expression of Foxp3 in
CD4+CD25-nafve T cells endows them with suppressive functions 33,34, Thanks to the
generation of a knock-in Foxp3-GFP mice, in which the complete eGFP sequence was
inserted in the first exon of the Foxp3 gene3S, it was possible to specifically identify
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which cell subset expresses this transcription factor, It was found that Foxp3 is mainly
expressed (>99,8%) by TCRj3+ T cells, both in thymus and periphery, while
macrophages, DC cells, NKT cells, NK cells, B lymphocytes and non hematopoietic
cells are deficient in Foxp3 35, Foxp3 expression was confirmed in both CD25+ and
CD25-CD4+ T cells, whose suppressive ability was confirmed with different functional
assays, In these studies, Foxp3 emerged as the most specific Treg marker, since CD25
and other surface molecules constitutively expressed by Treg cells, such as
glucocorticoid-induced TNF receptor family-related gene (GITR), cytotoxic T
lymphocytes-associated antigen 4 (CfLA-4) and OX40, are up-regulated also by
activated Teff cells 35,36, Treg cells were able to differentiate both in the thymus, from
early common precursors, and in the periphery, from nalve CD4+Foxp3- T cells in
response to different immunosuppressive stimuli 37.38 the former are named natural Treg
(nTreg), the latter induced (or adaptive) Treg (i'Ireg). In the thymus, Foxp3 expression
is predominantly found at the stage of CD4+ single positive (SP) cells, although a small
percentage of cells expressing Foxp3 is found in the CD8+ SP, CD4+CD8+ double
positive (DP) and CD4-CD8- double negative (DN) stages of thymic development".
Although the precise signals that guide nTreg differentiation, and consequently Foxp3
expression, are not yet well understood, the strong interaction between TCR and
MHC/self-antigen presented by DC seems to have a crucial role in this process 38.39,32.
Also, IL-2 is a critical player in nTreg differentiation process 37, It was demonstrated
that mice with alteration in the IL-2IIL-2R pathway or in IL-2 signals transducers, like
StatS and Jak3 40, or treated with anti-IL-2 antibody 27 have fewer Treg cells, both in
thymus and periphery, compared to wt mice, Furthermore, their Treg cells express
Foxp3 at lower levels than wt Treg, resembling immature and non-suppressive
regulatory T cells 41, In 2008 Hsieh and Ferrar, in two distinct studies, using a two-step
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model described nTreg development in the thymus as dependent on TCR and IL-2
signaling 42,43. They proposed that nTreg precursors (CD4+CD2ShighFoxp3iCR+), after
receiving strong stimulation via TCR, further up-regulate CD2S, thus becoming more
sensitive and responsive to IL-2. This enhanced IL-2 responsiveness eventually
promotes Foxp3 expression 42.43. In addition to the stimuli provided by TCR and IL-2,
other molecules were indicated as relevant in the nTreg differentiation process. Among
these the costimulatory molecule CD28 44 and the transcription factor NF-kB 45 were
demonstrated to be necessary for nTreg differentiation. Unlikely nTreg, iTreg
differentiate in periphery from narve T cells in response to different stimuli. iTreg
include different subsets of regulatory cells: Trl, Th3 and Treg indistinguishable from
nTreg 46. When naive T cells are in presence of high amount of IL-IO they acquire a
suppressive phenotype and are defined Tr 1 cells. These cells produce abundant IL-l 0,
but do not secrete TGF~. In contrast, Th3 cells are both induced by TGF~ and produce
. it themselves 47. Both Trl and Th3 cells, even if endowed of suppressive functions, do
not express Foxp3. Naive lymphocytes can also differentiate in iTreg cells that are
indistinguishable from nTregs when they are in the presence of TGF~ and receive
insufficient antigen stimulation by immature/tolerogenic APe 46.
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Fig.1.1.3.2 Representative scheme of Tregulatory cells subsets.
CD4+CD25+FOXP3+ (forkhead box P3) natural regulatory T cells (TReg cells) inhibit the
proliferation of CD25- T cells. The mechanism of suppression seems to be multifactorial and
includes cell-cell contact. CD4+CD25+ TReg cells express cytotoxic T-lymphocyte antigen 4
(CTLA4), which interacts with CD80 and/or CD86 on the surface of antigen-presenting cells
(APCs) such as dendritic cells (DCs), and this interaction delivers a negative signal for T-cell
activation. There is also some evidence that secreted or cell-surface transforming growth
factor-B (TGF-B) or secreted interleukin-10 (IL-10) might have a role in suppression mediated
by natural regulatory T cells. Image is adapted from Kingston H. G. Mills Nature Reviews
Immunology 4,841-855 (November 2004).
1.1.3.3 The biology of myeloid-derived suppressor cells
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of
cells that expands during cancer, inflammation and infection, and that has the ability to
suppress T-cell responses. These cells constitute a unique component of the immune
system that regulates immune responses in healthy individuals and in the context of
various diseases. In addition to their suppressive effects on adaptive immune
responses, MDSCs have also been reported to regulate innate immune responses by
modulating the cytokine production of macrophages.· Non-immunological functions of
MDSCs have also been described, such as the promotion of tumor angiogenesis,
tumor-cell invasion and metastasis. MDSCs are a heterogeneous population of
activated immature myeloid cells that have been prevented from fully differentiating
into mature cells. Schematic representation of different MDSCs population in distinct
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tumor model is shown in Table.I. MDSCs lack the expression of cell-surface markers
that are specific for monocytes, macrophages or DCs and are comprised of a mixture
of myeloid cells with granulocytic and monocytic morphology'f. In mice, MDSCs are
characterized by the co-expression of the myeloid lineage differentiation antigens
Ly60, Ly6C and CD11b. Based on the level of expression of Ly60 and Ly6C antigens
MDSCs in mice could be further divided in two subsets: granulocytic MDSCs (0-
MDSCs) have a CDllb+Ly60+Ly6C)OWphenotype, whereas MDSCs with monocytic
morphology are CDllb+Ly60-Ly6Chigh• Normal bone marrow contains 20-30% of
cells with this phenotype, but these cells make up only a small proportion (2-4%) of
spleen cells and are absent from the lymph nodes in mice. In humans, MDSCs are most
commonly defined as CD14"CD11b+ cells or, more narrowly, as cells that express the
common myeloid marker CD33 but lack the expression of markers of mature myeloid
and lymphoid cells and the MHC-class-II molecule HLA-DR. MDSCs have also been
identified within a CD15+ population in human peripheral blood. Different MDSC
subsets are characterized on the basis of their immune phenotype (see Table.2). In
healthy individuals, immature myeloid cells with the described phenotype comprise
-0.5% of peripheral blood mononuclear cells. MDSCs were first characterized in
tumor-bearing mice and in patients with cancer. Inoculation of mice with
transplantable tumor cells, or the spontaneous development of tumors in transgenic
mice with tissue-restricted oncogene expression, results in a marked systemic
expansion of these cells. In addition, up to a tenfold increase in MDSC numbers
characterize the blood of patients with different types of cancer. In many mouse tumor
models, as many as 20-40% of nucleated splenocytes are represented by MDSCs (in
contrast with the 2-4% observed in tumor-free mice).
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Tumor type MDSC phenotype References
Colon carcinoma (CT26, Salvadori et al. 2000;
C26 cell lines); Melanoma CDlIb/Gr-l Gabrilovich et al.
(BI6); fibrosarcoma (C3, 200 I .Kusmartsev et
15-12 RM) al. 2000, 2005; Liu
et al. 2003
Breast cancer (TSI A) and CD 11b/Gr-1 ICD31 Young et aI., 1996;
Lung cancer Bronte et al. 1999;
Bronte et al. 2000
Colon Carcinoma (C26- COil b/Gr-11F4/80/1LRa Gallina et aI., 2006;
GM), Breast cancer (4Tl), Dolcetti et aI., 2009
Sarcoma (MCA203)
Timoma (EL-4), linfoma COil b/Gr-I/F4/80/CDIISinl Kusmartsev et aI.,
(EG?, BW-Sp3), Colon 2005; Movahedi et
carcinoma ( MCA26) aI., 2008; Huang et
al.,2006
Ovarian cancer CD II b/Gr-1 ICD80 Yang et aI., 2006
Transgenic mamary mouse CD II b/Gr-1 ICD31 Melani et al. 2003;
model ( BalbNeuT) Melani et aI., 2007
Table.1 Immune phenotype of different MDSC recruited in transplantable or
transgenic mouse tumor model.
Tissue c.UpopulatlOll Subpopul.tlons Phenotype
M~ .. DC. NO COt Ic'r4/80 GR\ MHC.II'
lymphoid Conventional DC,- CDl1c'CDt lb'MHC-II'C020S'F4/80 GRI COltS ....Ofgans
P\illifTlacytoldOCs cone-coue B220·SIGlEC·H-GR1'F<4/8O"
Monocyte, NO cons-r Y6ClY6G-CD11c'CQ115'
Re$\dcnt monocytes CDllb'lY6C-lY6G CD11S'MHC-1I F4/6O"'C011c
hlttammll101'y monexyte) COllb'LY6C"lY6G COl tS'MHC-1I f4/80'CD11c
MlICrophages NO F'V80'COl1b'GR 1
M 1macrophqs INOS'IL·t2'CD86'MHC·11'"
M2mac::roph.ages CDl06'CDt63'CDWARG1'MHC-li"1L-I0'll-4R.:!'
nZlt'YMt'
GnmulOC)1e5 Various Collb'lV6<;-LV6C-f<4/80 COlle
M"" .. MOSCs NO Collb'GRl'CDllc F<4/8O" COtH'
tumours
Polymorphonuclear MOSCs CDI1b'CRl"l'r'oc-LY6G-CO<49d
Monocytic MOSes COlI b'eR I ooIotLYbe"lYbG"C0<49d'
Human DC,' NO UN HLA·DR'BDCAt'C0209'
blood Conventional DC:s1 UN COllc'CDllb'C033'BOCAI'S0CA3'OC,SIGN'
Plasmacytoid DC, LIN CDI23'80CAz'SOCM'
MOllocyte,' NO CDWHLA·OR'COI$
MiKropnages NO (01<4'C068'
M I mac:rophagn INQS'll·12-C086'HLA-OR'
M2macropllages CD206'CD163'CDWHLA·DR-ll-IO'CDIH'
Grllf1Ulocyte~ NO COIS'COI<4 C066b'CDI6'
Humall MOSCs' NO UN CDllb'HLA OR COn'
Polymorphonuc:iear Moses In ttddition to the above MOSC phenot)1>e,I~
cells express COl Sand/or CD66b
Monocycle Moses CD}3'COl4'HLA DR-'
"RGt.qIYM 1:BOCA I. blood DC"'I~ 11.1\0 kMWnasCDlc): BOCA2. blood DC "lIlQefll f.t,okn()wfl~CD101kBOCA},
Table2. Phenotypic characterization usedfor isolated MDSC populations. Adapted
from Gabrilovich DI, Review Immunology, 2012 Mar 22:12(4).
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1.1.3.3.1 Soluble factors involved in MDSCs recruitment and function
Factors that induce MOSC expansion include cyclooxygenase-2 (COX2),
prostaglandins, stem-cell factor (SCF), macrophage colony-stimulating factor (M-
CSF), IL-6, granulocyte/macrophage colony-stimulating factor (GM-eSF) and
vascular endothelial growth factor (VEGF) 49,50. The signaling pathways in MOSCs
that are triggered by the majority of these factors converge on Janus kinase (JAK)
protein family members and downstream pathways that induce activation of
transcription 3 (STAT3), which are signaling molecules involved in cell survival,
proliferation, differentiation and apoptosis. STAT3 is arguably the main transcription
factor that regulates the expansion of Moses. MOSCs from tumor-bearing mice have
markedly increased levels of phosphorylated STAT3 compared with IMCs from naive
mice. Exposure of hematopoietic progenitor cells to tumor-cell-conditioned medium
resulted in the activation of JAK2 and STAT3 and was associated with an expansion of
Moses in vitro, whereas inhibition of STAT3 expression in hematopoietic progenitor
cells abrogated the effect of tumor-derived factors on MOSC expansion. Ablation of
STAT3 expression in conditional knockout mice or selective STAT3 inhibitors
markedly reduced the expansion of MOSCs and increased T-cell responses in tumor-
bearing mice. STAT3 activation is associated with increased survival and proliferation
of myeloid progenitor cells, probably through upregulated expression of STAT3 target
genes including B-cell lymphoma XL, (BCL-XL), cyclin 01, MYC and survivin.
Accordingly, abnormal and persistent activation of STAT3 in myeloid progenitors has
been shown to prevent their differentiation into mature myeloid cells and thereby
promotes MOSe expansion. Recent findings suggest that STAT3 also regulates MOSC
expansion by inducing the expression of SI OOA8 and SI OOA9 proteins. In addition, it
has been shown that MOSes also express receptors for these proteins on their cell
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surface. SI OOA8 and SI OOA9 belong to the family of SI 00 calcium-binding proteins
that have been reported to have an important role in inflammation. STAT3-dependent
upregulation of SI 00A8 and SI OOA9expression by myeloid progenitor cells prevented
their differentiation and resulted in the expansion of MDSCs in the spleens of tumor-
bearing and naive SI 00A9-transgenic mice. By blocking the binding of SI 00A8 and
Sl00A9 to their receptors on MDSCs in vivo with a carboxylated glycan-specific
antibody reduced MDSC levels in the blood and secondary lymphoid organs of tumor-
bearing mice. Although the mechanisms involved require further investigation, these
studies suggest that SI 00A9 and/or SI 00A8 proteins have a crucial role in regulating
MDSC expansion, and may provide a link between inflammation and immune
suppression in caocer".
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Fig. 1.1.3.3.1 Molecular mechanism affecting myeloid cells lineage proliferation and
expansion.
Soluble factors, secreted by tumor microenvironment, affect myeloid cells progenitors as well
as mature myeloid cells and regulate the activity of different transcriptional factors that in turn
target the synthesis of different proteins. Adapted from Gabrilovich DJ, Review Immunology,
2012 Mar 22: 12(4).
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1.1.3.3.2 Mechanisms of MDSC suppressive activity
A large number of studies have shown that the immunosuppressive functions of
MDSCs require direct cell-to-cell contact, which suggests that they act either through
cell-surface receptors and/or through the release of short-lived soluble mediators.
Historically, the suppressive activity of MDSCs has been associated with the
metabolism of L-arginine. L-arginine serves as a substrate for two enzymes: iNOS,
which generates NO, and arginase, which converts L-arginine into urea and L-
ornithine. MDSCs express high levels of both arginase and iNOS, and a direct role for
both of these enzymes in the inhibition of T-cell functions is well established. Recent
data suggest that there is a close correlation between the availability of arginine and the
regulation of T-cell proliferation. The increased activity of arginase in MDSCs leads to
enhanced L-arginine catabolism, which depletes this non-essential amino acid from the
microenvironment. The shortage of L-arginine inhibits T-cell proliferation through
several different mechanisms, including decreasing their CD3 expression and
preventing their upregulation of the expression of the cell cycle regulators cyc1in D3
and cyclin-dependent kinase 4 (CDK4). NO suppresses T-cell function through a
variety of different mechanisms that involve the inhibition of JAK3 and STAT5 in T
cells, the inhibition of MHC class II expression and the induction of T-cell apoptosis
(Fig.l.1.3.3.2).
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Fig. 1.1.3.3.2 Mechanisms of MDSC-dependent inhibition of T cells activity.
Myeloid-derived suppressor cells (MDSCs) inhibit efficient anti tumor T cell responses via
different mechanisms. a) Tumor-associated MDSCs induce the development of regulatory T
(Treg) cells or expand existing TReg cell populations trough the calcium-binding proteins
SlOOA8 and SlOOA9 and SlOOA9. These effects are mediated in part through the activation of
receptor for advanced glycation end-products (RAGE) and are responsible for the increased
production of reactive oxygen species (ROS) by MDSCs. b) Tumor-associated myeloid cells
deprive T cells of amino acids that are essential for their growth and differentiation. c) Tumor-
associated myeloid cells release oxidizing molecules, such as hydrogen peroxide (H202) and
peroxynitrite (ONOO-), that nitrosylate components of the T cell receptor (TCR) signaling
complex. d) Tumor-associated myeloid cells can also interfere with T cell migration and
viability. Adaptedfrom Gabrilovich DI, Review Immunology, 2012 Mar 22:12(4).
1.1.3.3.3 Reactive oxygen species (ROS).
Another significant factor that contributes to the suppressive activity of MDSCs
are ROS. Increased production of ROS has emerged as one of the main characteristics
of MDSCs in both tumor-bearing mice and patients with cancer. Inhibition of ROS
production by MDSCs isolated either from mice or patients with cancer completely
abrogated the suppressive effect of these cells in vitro. Interestingly, ligation of
integrins expressed on the surface of MDSCs was shown to contribute to increased
ROS production following the interaction of MDSCs with T cells. In addition, several
known tumor-derived factors, such as TGFp, IL-IO, IL-6, IL-3, platelet-derived growth
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factor (PDGF) and GM-CSF, can induce the production of ROS by MDSCS48, 51.
Recent findings indicate that different subsets of MDSCs might use different
mechanisms to suppress T-cell proliferation. The granulocytic subset of MDSCs was
found to express high levels of ROS and low levels of NO, whereas the monocytic
subset expressed low levels of ROS and high levels of NO and both subsets expressed
ARG1. Interestingly, both populations suppressed antigen-specific T-cell proliferation
to an equal extent, despite their different mechanisms of action. Consistent with these
observations, Movahedi et al. also reported two distinct MDSC subsets in tumor-
bearing mice, one that consisted of mononuclear cells that resembled inflammatory
monocytes and the other that consisted of polymorphonuclear cells that were similar to
immature granulocytes'", Again, both populations were found to suppress antigen-
specific T-cell responses, although by using distinct effector molecules and signaling
pathways. The suppressive activity of the granulocytic subset was ARG l-dependent, in
contrast to the STAT1- and iNOS-dependent mechanism of the monocyte fraction 53,
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1.1.3.4 Therapeutic targeting of MDSCs
1.1.3.4.1 Promotion of myeloid-cell differentiation
One of the most promising approaches to targeting MDSCs for therapy is to
promote their differentiation into mature myeloid cells that do not have suppressive
abilities. Vitamin A has been identified as a compound that can mediate this effect:
vitamin A metabolites such as retinoic acid have been found to stimulate the
differentiation of myeloid progenitors into DCs and macrophages. Mice that are
deficient in vitamin A or that have been treated with a pan-retinoic-acid-receptor
antagonist show an expansion of MDSCs in the bone marrow and spleen. Conversely,
therapeutic concentrations of all-trans retinoic acid (ATRA) result in substantial
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decrease in the presence of MDSCs in cancer patients and tumor-bearing mice 50, 55.
ATRA induced MDSCs to differentiate into DCs and macrophages in vitro and in vivo.
It is probable that ATRA preferentially induces the differentiation of the monocytic
subset of MDSCs. whereas it causes apoptosis of the granulocytic subset. 56.
1.1.3.4.2 Inhibition of MDSC expansion
MDSC expansion is regulated by tumor-derived factors. Different studies have
focused on neutralizing the effects of these factors. SCF has been implicated in causing
MDSC expansion and the inhibition of SCF-mediated signaling by blocking its
interaction with its receptor, c-kit, decreased MDSC expansion and tumor
angiogenesis. Me/ani et al showed that inhibition of matrix metalloproteinase 9
function in tumor-bearing mice decreased the number of MDSCs in the spleen and
tumor tissues and resulted in a significant delay in the growth of spontaneous NeuT
tumors in transgenic BALB/c mice. In this setting. the authors showed that both tumor
and stromal cells express matrix metalloproteinase-9 (MMP-9), thereby increasing the
levels of pro-MMP-9 in the sera of tumor-bearing mice. Treatment with amino-
bisphosphonates (Zoledronic acid) impaired tumor growth, significantly decreased
MMP-9 expression and the number of macrophages in tumor stroma, and reduced
MDSC expansion both in bone marrow and peripheral blood by dropping serum pro-
MMP-9 and VEGF 49. The authors dissected the role of tumor-derived MMP-9 from
that secreted by stromal leukocytes by transplanting bone marrow from MMP-9
knockout mice into BALB-neuT mice. Although bone marrow progenitor-derived
MMP-9 had a major role in driving MDSC expansion, amino-bisphosphonate
treatment of bone marrow chimeras further reduced both myelopoiesis and the
supportive tumor stroma, thus enhancing tumor necrosis. Moreover, by reducing
MDSC, amino-bisphosphonates overcame the tumor-induced immune suppression and
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improved the generation and maintenance of antitumor immune response induced by
immunization against the pI 85/HER-2. These data revealed that suppression ofMMP-
9 activity breaks the vicious circle linking tumor growth and myeloid cell expansion,
and that amino-bisphosphonates trigger a specific MMP-9 inhibitory activity that may
extend their application beyond their current usage. Very recently, it has been shown
that amino-bisphosphonates could also inhibit MDSC activity by blocking the TGFp
axis that is crucial for their pro-tumoral function 57.
1.1.3.4.3 Inhibition ofMDSC function
Another way to inhibit MDSCs is to block the signaling pathways that regulate
MDSC production of suppressive factors. This might be achieved by targeting COX2.
COX2 is required for the production of prostaglandin E2, which in 3LL tumor cells
and mammary carcinoma has been shown to induce the upregulation of ARG 1
expression by MDSCs, thereby inducing their suppressive function58• Accordingly,
COX2 inhibitors were found to downregulate the expression of ARG1 by MDSCs,
which improved antitumor T-cell responses and enhanced the therapeutic efficacy of
immunotherapy 59. Similarly, phosphodiesterase-5 inhibitors such as sildenafil are able
to downregulate the expression of arginase and iNOS expression by MDSCs, thereby
inhibiting their suppressive function in growing tumors'". This resulted in the
induction of a measurable anti-tumour immune response and a marked delay of tumour
progression in several mouse models. The main categories of targeting agents used to
inhibit MDSC activity are listed in Table.3.
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Therapeutic agents T "Ill' uf cancer tested
Therapeutic agents TyIX of CUIIC\..'ftested Sinha p, El .1. ProSlllglandin El promotes remer progression by inducing
myeloid-derived sUPJrCssor cells. Cancer Res 2007
C~cloo,,) gcnasc-z inhibitors Mammary carcinornn (mice)
(SC58236)
Meillni C•.:I Ill. Amino-biphosphonetc-mcdiated MMP-9 inhibition breaks
the tumor-hone marrow axis responsible for myclosd-dcrivod :-Iuppre~1I'
cell expansion and mecrophngc infiltration in turner stroma. Cancer Res
2007
KIT-specific antibody Colon Carcinoma (mice)
Sermnl P. et .L Phospbodicstcrese-S inhibition augments endogenous
antitumor immunity by reducing myeloid-derived suppressor cell
function, J Exp Med 2006
Pan PY. er al
Reversion of immune tolerance in advanced malignancy. ruodnlauon of
myeloid derived suppressor cell development h~ blockade of stem-cell
factor function. BIOl"d 2008
De Sanlo C, et aJ Nnroespirin corrects immune dysfunction in tumor-
bearing hosts and promotes tumor eradication by cancer vaccination. Proc
Natl Acad Sci USA 2005
Amino-biphosphonetcs Mammarv tumors (mice)
Biphosphanere. sildennfil and Mammary carcinornetmicc)
tadalatil Colon Carcinoma (mice)
Fibrosarcoma (mice)
Nitrcespirin Colon Carcinoma (mice)
Ku~m.rI~e'tS. cl Ill.
All-trans-rcnnoic acid eliminates immature myeloid cells from tumor-
bearing mice lind improves the effect of vuccinetion. Ceuccr Res 2003;
l\Iirl.. N, et al. All-truns-rctinoic acid improves differentiation of myeloid
cells and immune response in cancer patients Cancer Re-s 2006
..-III-mms rctinoic acid
Lathers D. et .1.
Sarcoma, colon carcimoma (mice) Phase IB siudy to Improvc immune responses 1I\ heed and 1k:C\.. C8n~,.
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Table 3. Pharmacological regulation of MDSC in cancer.
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1.2 Cell intrinsic and environmental-mediated drug resistance.
Resistance to tumor therapy can be subdivided into two broad categories:
intrinsic (or de novo) and acquired resistance. Acquired resistance develops over time
as a result of sequential genetic changes that ultimately culminate in complex therapy-
resistant phenotypes. One form of de novo drug resistance is the environment-mediated
drug resistance (EMDR), in which tumor cells are transiently protected from apoptosis
induced by either chemotherapy, radiotherapy or receptor-mediated cell death.
1.2.1 Enviromental-mediated drug resistance (EMDR)
This form of drug resistance arises from an adaptive reciprocal cross-talk
between tumor cells and the surrounding stroma 61. EMDR is rapidly induced by
signaling events that are initiated by factors present in the tumor microenvironment
and can be subdivided into two categories: soluble factor-mediated drug resistance
(SFM-DR), which is induced by cytokines, chemokines and growth factors secreted by
fibroblast-like tumor stroma; and cell adhesion-mediated drug resistance (CAM-DR),
which is mediated by the adhesion of tumor cell integrins to stromal fibroblasts or to
components of the extracellular matrix (ECM), such as fibronectin, laminin and
collagen as shown in Table.4. Notably, EMDR is transient and appearing only when
tumor cells are in contact with the microenvironment, and reverts rapidly when tumor
cells are removed from the microenvironment.
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Table.4 Schematic representation of EMDR mechanisms exerted by different tumors
Meads M4, Clin Cancer Res 14; 2519 (May, 2008).
1.2.2 CAM-DR (Cell-adhesion mediated drug resistance)
CAM-DR is particularly involved in conferring drug resistance in hematologic
tumors in response to various chemotherapeutic agents 62. CAM-DR mostly depends
on the engagement of integrin receptors as the adhesion mediated by these receptors
has been shown to influence cell survival and prevent programmed cell death. An
example of the role of CAM-DR in drug resistance comes from multiple myeloma.
This disease is mostly incurable mainly because of CAM-DR. In this context, Damiano
et al have shown that human myeloma cells after doxorubicin or melphalan treatment
increase the expression ofVLA-4 (alpha4betal) and VLA-5 (alpha5betal) integrin that
are fibronectin (FN) receptors, thus increasing cell adhesion and conferring drug
resistance. The induction of VLA-4 and VLA-5 was reversible and reduced by drug
removal from the culture medium. In another study performed on multiple myeloma,
Noborio-Hatano K et al (oncogene 2009) performed a functional screening by using
short hairpin RNA (shRNA) to define the molecule(s) responsible for CAM-DR of
multiple myeloma 63. Using four myeloma cell lines (KHM-IB, KMS12-BM,
RPMI8226 and U266) and primary myeloma cells, they identified CD29 (betal-
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integrin), CD44, CD49d (alpha4-integrin, a subunit of VLA-4), CD54 (intercellular
adhesion molecule-l (ICAM-I», CD138 (syndecan-l) and CD184 (CXC chemokine
receptor-4 (CXCR4» as major adhesion molecules expressed in multiple myeloma.
shRNA-mediated knockdown of CD49d but not CD44, CD54, CD138 and CD184
significantly reversed CAM-DR of myeloma cells to vincristine, doxorubicin and
dexamethasone. Interestingly, it was also showed that bortezomib was relatively
resistant to CAM-DR because of its ability to specifically downregulate CD49d
expression. This property was unique to bortezomib and was not observed in other
anti-myeloma drugs. Pretreatment with bortezomib was able to ameliorate CAM-DR
of myeloma cells to vincristine and dexamethasone, a finding suggesting that a
combination of bortezomib and conventional anti-myeloma drugs might be useful in
overcoming CAM-DR of MM. EMDR also plays an important role in determining the
extent of tumor response to therapies in solid tumors. In small cell lung cancer
(SCLC), ~l-mediated adhesion of tumor cells to ECM protects tumor cells from
chemotherapy-induced apoptosis by activating a tyrosine kinase pathway 64. Similarly
to SCLC also breast carcinoma 6S chemoresistance involves integrin activation. In
humans, ~1 integrin expression is also a prognostic factor for metastatic melanoma".
1.2.3 SFM-DR (Soluble factor mediated drug resistance)
SFM-DR depends on soluble factors released in the tumor microenvironment.
Interestingly, a dynamic interaction between tumor cells and their stroma is required to
produce the soluble factors that mediate drug resistance as Nefedova et al ss reported
that conditioned medium from stromal cells provided protection only if it was collected
from cells grown in co-culture with myeloma cells. Consistent with this observation,
IL-6 and stromal cell-derived factor 1 (SDF-l), the most widely studied mediators of
SFM-DR, are known to mediate resistance to various chemotoxic compounds in in
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vitro EMDR models of hematological and epithelial cancer 67, 68, 69, 70, 71 and are
produced at higher levels in tumor-associated stroma than in normal bone marrow
stroma. Recently, Perez et al. extended these findings by using immortalized stromal
fibroblasts and conditioned medium from patient bone marrow stroma to show that
paracrine interaction between myeloma cells and stroma is also required to prevent
myeloma cell lines from binding to death receptor for TNF-related apoptosis-inducing
ligand. IL-6 was found to contribute to this effect by increasing the expression of the
anti-apoptotic protein FLIP. An earlier work by Catlett-Falcone et al. demonstrated
that IL-6-induced signal transducer and activator of STAT-3 protects myeloma cells
from FAS-mediated apoptosis by upregulating transcription of the anti-apoptotic
molecule BCL-XL• 68.
1.2.4 EMDR targeting as apotential way to overcome drug resistance.
Cancer cells and their associated stroma coexist in an evolving ECM and
soluble factor milieu that is molded by their interaction. Reciprocal integrin- and
soluble factor-mediated signaling interactions between these two groups of cells induce
a transient EMDR phenotype in tumor cells, protecting them from therapy until more
complex acquired drug resistance phenotypes can develop. Therefore, stroma-induced
signaling pathways associated with the tumor microenvironment are increasingly being
targeted by therapeutic approaches intent on combating environment-mediated drug
resistance. In this context, Moshaver et al. 72 demonstrated that chemotherapy
decreased the ability of BM stromal cells to protect primary acute AML cells from
chemotherapy. Using stromal fibroblasts that were pretreated with chemotoxics, they
showed that treatment of stroma reduced the ability of primary AML and AML cell
lines to proliferate and survive subsequent exposure to chemotherapy, suggesting that
these cells must also need to develop resistance to therapy to ensure tumor survival. An
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earlier study by Spiotto et al. suggested that targeting tumor stroma with
immunotherapy in vivo could be an effective strategy by showing that bystander
elimination of subpopulations of antigen loss variant tumor cells by cytotoxic T cells
was possible only when parental tumor cells expressed sufficient amounts of antigen to
be cross-presented by tumor stroma cells, allowing stromal cells themselves to be
targeted for killing by T cells 73. Later work by Zhang et al. from the same group
showed that irradiation or chemotherapy could also increase cytotoxic T cell killing of
established turnors by causing enough antigen to be released from tumor cells to target
antigen-presenting stroma for destruction. They later verified the important role of
stroma in this effect by showing that cytotoxic T cell killing of only major
histocompatibility complex (MHC)-restricted tumor stroma causes long-term
inhibition of tumor growth. 74. Collectively, these data illustrate the important role of
stroma in tumor survival and resistance to therapy and suggest that directly targeting
stroma and stroma-mediated pathways might be an effective means of turnor therapy.
1.2.5 Epithelial to mesenchymal transition and drug resistance
Increasing evidence suggest that epithelial to mesenchymal transition (EMT) is
associated with increased drug resistance. The EMT is a highly coordinated process
and a multistep event during which epithelial cells lose epithelial characteristics and
assume properties that are typical of mesenchymal cells. Cells that have undergone
EMT can migrate out of their epithelial layers to distant points and either remain
mesenchymal or redifferentiate into epithelial cells by a process known as
mesenchymal-epithelial transition (MET). This process also been involved In
decreasing the tumor grade. In human breast cancer, Triulzi et al. have identified a
subgroup of breast tumors up-regulating EMT genes in both neoplastic and adjacent
stromal cells, and showing increased tumor grade 7S and drug resistance. EMT is best
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characterized for its role in embryonic development; induction of EMT is necessary for
formation of the mesoderm and endoderm during gastrulation and for delamination of
the neural crest. Following EMT, disseminated mesenchymal cells act as progenitors
for many different tissue types. A number of distinct molecular processes, intrinsic to
the tumor cell, are engaged in order to initiate an EMT and enable it to reach
completion, including activation of transcription factors, expression of specific cell-
surface proteins, reorganization and expression of cytoskeletal proteins, production of
ECM-degrading enzymes, and changes in the expression of specific microRNAs. A
new concept is that besides the cell-intrinsic molecular events leading to EMT, also the
immune cells present in the tumor microenvironment might promote EMT. In this
context, recent findings have revealed that activated CD8 T cells can stimulate
mammary epithelial tumor cells to undergo epithelial-mesenchymal transition (EMT)
and to become breast cancer stem cells (BCSC) acquiring greatly increased
tumorigenic capability and chemotherapeutic resistance 76. Different myeloid cells
have been also involved in EMT: in colon cancer models, BM-derived CDllb+Jag2+
cells have been shown to promote EMT through a Notch dependent pathway which
can be blocked either with neutralizing antibodies, or by decreasing the tumor-
infiltrating CDllb+Jag2+ cells 77 (Fig.l.2.5). Using a spontaneous murine model of
melanoma, it has also been showed that MDSC infiltrates the primary tumor and
actively promotes cancer cell dissemination by inducing epithelial-mesenchymal
transition (EMT). CXCL5 was found to be the main chemokine attracting MDSC to
the primary tumor, whereas TGF-~, EGF, and HGF were the signaling pathways
involved in this process 78.
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Fig 1.2.5 Tumor plasticity is regulated by a connection between extracellular signal
and EMT transcription factors.
TGF-fJ, WNT proteins, platelet-derived growth Jactors (PDGFs) and interleukin-ti (IL-6),
HGF, EGF arising from autocrine or paracrine signaling networks can activate intracellular
signaling Jactors that influence the activation of transcriptional factors involving in EMT
program from Wai Leong Tam and Robert A. Weinberg, Nature Medicine (November 2013).
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1.3.Matricellular proteins
Matricellular proteins form a group of extracellular matrix (ECM) proteins,
unlike collagens, that do not have a primary structural role, but rather function as
modulators of cell-matrix interactions. Members of the group, such as thrombospondin
(TSP)-1,TSP-2, SPARC, tenascin (TN)-C, and osteopontin (OPN), have been shown to
participate in a number of processes related to tissue repair 79. Tumor stroma
continuously adapts to and coevolves with tumor enlargement through processes
mimicking wound healing. Certainly, understanding how matricellular proteins are
involved in wound healing will allow us to evaluate their role in cancer and probably
to investigate the link of inflammation and cancer. SPARC (Secreted Protein Acidic
and Rich in Cysteine, also known as osteonectin or BM-40) is a 32-kDa
multifunctional glycoprotein that belongs to the matricellular group of proteins. It
modulates cellular interaction with the extracellular matrix (ECM) by its binding to
structural matrix proteins, such as collagen and vitronectin, and to surface receptors
and growth factors. Its expression is spatially and temporally confined during
embryogenesis, tissue remodeling, repair and tumorigenesis. SPARC functions to
regulate cell-matrix interactions and thereby influences many important physiological
and pathological processes. 80
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1.3.1 Structure and properties of SPARe
SPARC is a 32 kD protein, but the secreted form migrates at 43 kD on SDS-
PAGE, in part due to the addition of carbohydrate 81. The vertebrate SPARC gene
encodes proteins of 298-304 amino acids (aa), including three distinct modules, as
shown in Fig 1.3.1 Module I (aa 3-51), previously termed domain I 82, is encoded by
exons 3 and 4, is highly acidic, and binds 5-8 Ca2+ ions with a Kd of 10-3-10-5 M.
The structure of this module has not yet been solved. This NH2-terminal domain
contains immunodominant epitope(s) and binds to hydroxyapatite. It is the major
immunological epitope of SPARC and also the region that is the most distinct from the
other members of the SPARC gene family. Therefore, antibodies against SPARC have
not been found to cross-react with, or recognize, the SPARC-like protein 83. Module II
(aa 52-132) is encoded by exons 5 and 6 and contains 10 Cys and an N-linked
complex carbohydrate. The sequence encodes a structure that is homologous to a
repeated domain in follistatin, a protein that binds to activin and inhibin, members of
the TGF- superfamily, and agrin, which induces aggregation of nicotinic acetylcholine
receptors. Module II also contains bioactive peptides that have different effects on
endothelial cells. Peptide 2.1 (aa 55-74), part of the EGF-like hairpin, inhibits the
proliferation of endothelial cells and peptide 2.3 (aa 113-130), containing the Cu2+
binding sequence GHK and part of the Kazal protease inhibitor-like region, stimulates
endothelial cell proliferation and angiogenesis 84. Module III (aa 133-285, exons 7-9),
formerly designated as the EC module, like Module II contains a sequence designated
peptide 4.2 (aa 254-273), which has been shown to bind to endothelial cells and to
inhibit their proliferation 85,86. The fibril-forming collagen types I, III, and V and the
basement membrane collagen type IV bind to the EC module of SPARC in a Ca2+-
dependent fashion.
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Stimulates angiogenesis
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Binds PDGF
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Inhibits cell proliferation
Induces metalloproteinases
Fig.l.3.1 Crystallographic structure of human SPARe.
a. The acidic domain is shown in green, the follistatin-like domain in red and the extracellular
domain in purple. h. Functional properties oj the three protein domains. Abbreviation:
SPARe, secreted protein acidic and rich in cysteine (also known as osteonectin or BM-40).
From Bradshaw, A. D. & Sage, E. H. J. Clin. Invest. 107, 1049-1054 (2001).
1.3.2 Expression of SPARC
SPARC is expressed at high levels in breast tissue, is distributed widely III
many other tissues and cell types, and is associated generally with remodeling tissues,
e.g., tissues undergoing morphogenesis, mineralization, angiogenesis, and pathological
responses to injury and tumor genesis. 87. Although SPARC KO mice are born without
obvious abnormalities, targeted disruption of the SPARC locus in mice has shown that
SPARC is important for lens transparency, as SPARC-null mice develop cataracts
shortly after birth. An impaired wound healing in mice deficient in SPARC has been
reported 88. Additionally, over expression of SPARC in nematodes also resulted in
developmental abnormalities including an uncoordinated (Unc) phenotype in the Fl
generation. Furthermore, worms overexpressing SPARC did not produce any viable
offspring 89. These results along with the data from SPARe-null mice, indicate that the
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appropriate and regulated expression of SPARC is necessary for normal development.
The level of expression of SPARC in the heart during fetal development is high, but
after birth it is reduced and almost absent during adulthood. In recent studies, the up-
regulation of SPARC expression has been observed in the injured heart. Up-regulation
of SPARC in the myocardium of adult rats has been observed during the remodeling of
cardiac extracellular matrix during beta adrenergic stimulation 90. The increase of
SPARC expression in the heart was reported in response to myocardial infarction as
well 91. SPARC mRNA expression paralleled the upregulation of type 1 collagen
mRNA after myocardial infarction implicating a role for SPARC in the process of scar
formation. But, so far, the protein levels of SPARC in the heart have not been studied.
Interestingly, cardiac myocytes plated on fibronectin (FN) showed elevated expression
of SPARC in vitro. Whether the absence of SPARC may lead to an altered formation
of collagen in the normal heart is yet unknown.
1.3.3Interaction ojSPARCwit/, ECJlproteins
Vitronectin. SPARC binds preferentially to the multimeric form of vitronectin
(mVN) rather than to the circulating plasma form, a fact indicates that these
interactions are preferentially taking place within the ECM environment rather than in
the soluble phase. Interestingly, active PAI-l is able to induce directly the
conformational transition from plasma to multimeric vitronectin. Moreover, contact
with the vitronectin binding site of PAI-I is required because the monoclonal antibody
2C8 prevented ECM protective activity of PAl -I. Finally, SPARC was demonstrated
to induce PAI-I production in some cells 92. VitronectinlPAI-1 complexes are linked to
SPARC collagen type I-rich sites and additional observations also indicate that PAI-I
itself might have a major impact on the motility of cells. Competition studies with
basic vitronectin-derived peptides, heparin and heparan sulphate, also demonstrated
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that the heparin-binding site of multimeric vitronectin is an essential region for the
interaction with SPARC. In contrast, plasma vitronectin, in which this region is
cryptic, displayed virtually no binding to SPARC. This result indicates that the
conformational transition of plasma vitronectin to the multimeric form is required for
binding with SPARC. The fact that interactions with vitronectin can be inhibited by
salt concentrations greater than 0.2 M and by Ca2+ ions (0.5± 1 mM) indicates the
involvement of Ca2+ binding acidic domain(s) of SPARC. These results agreed with
observation that the complete or partial removal of domains III and IV (EC module), or
a synthetic EF-hand, decreased the binding of SPARC to vitronectin. On the other
hand, the partial deletion of domain I enhanced binding, probably because
conformational changes in SPARC due to the internal binding of domain I to the C-
terminal portion are able to affect its interaction with vitronectin.
Collagens. The binding of SPARC to collagen depends on SPARC N-
glycosylation at Asn 99, a specific and highly conserved site 939495. Interestingly, BM-
40 from bone and platelets migrates differently in sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE), and enzymatic digestion with N-
glycosidase F and endoglycosidase H showed that the difference is due to variable N-
glycosylation with the bone-derived protein carrying predominantly high-mannose
oligosaccharides, whereas those on platelet BM-40 are mainly of the complex type",
The differences in the type of N-glycans have functional consequences, as the bone
form of the protein binds to collagen I, III, and V, whereas the platelet form does not.
The removal of N-linked oligosaccharides by N-glycosidase F treatment increases the
affinity of BM-40 from both bone and platelets to collagen V to reach equal levels of
affinity. Site-directed mutagenesis shows that only the glycosylation of Asn99 affects
collagen binding 97. The collagen affinity of BM-40 is of great functional importance.
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The collagen affinity of BM-40 is of great functional importance. In fact, the collagen
I-deficient Mov-13 mouse line does not retain SPARC in the extracellular matrix 98
and dermal collagen fibrils in SPARC-null mice have a decreased diameter and a
reduced tensile strength 99. Not only glycosylation but other forms of post-translational
modification of SPARC modulate the collagen affinity. Limited proteolytic cleavage of
SPARC occurs in tissues, and treatment with matrix metalloproteinases increases its
affinity for collagens 7-20-fold due to a cleavage in helix {alpha}C100 in the
extracellular calcium-binding 101. Indeed, deletion of helix {alpha}C in recombinant
SPARC gives a similar increase in binding affinity, and X-ray crystallography shows
that this is due to the removal of a steric constraint on the binding site, which was
mapped to a loop between the two EF-hands in the extracellular calcium-binding
domain 102. One important aspect is that a different type ofN-glycosylation can occur
in SPARC, and it has been demonstrated that different types of N-glycosylation can
affect in a different manner various cell behaviors. In experimental tumor models the
most common aberrant N-glycosylations are an increase in terminal sialylation and a
shift to more highly branched N-linked oligosaccharides; it has been shown that the
metastatic potential of tumor cells correlates with these changes 103.104,105.
Glycosylation also has been implicated in the regulation of CD44-mediated cell
binding of hyaluronan. Interestingly, N-linked oligosaccharides can both enhance and
reduce the CD44 affinity for hyaluronan depending on the specific structure of the
glycan 106. Regarding SPARC certain work performed by Kaufmann and colleagues in
2001 demonstrated a highly variable N-glycosylation ofSPARC derived from different
sources 107. The authors speculated that the type of glycosylation is dependent on the
glycosyl transferase repertoire of the producing cell type, rather than being directed by
the acceptor protein. It is known that SPARC binds to collagen, but the functional
48
significance of the interaction of SPARC with collagen in tissues is not clear. Collagen
may serve as a storage site for SPARC in the ECM or may directly modulate the
activity of SPARC, e.g. its counteradhesive or anti-proliferative functions. The fact
that proteolytic cleavage of SPARC results in a higher affinity for collagen indicates
that collagen is a potentially important ECM ligand for SPARC 108. Interestingly,
SPARC has been shown to increase the production and activity ofMMPs 109,110. These
results suggest that SPARC might participate in an autocrine or paracrine positive
feedback loop. For example, SPARC stimulates the expression and activity of MMP-2
and in turn, MMP-2 proteolytic ally cleaves SPARC, which increases the affinity of
SPARC for collagen and presumably its localization to the basement membrane, an
efficacious site for an anti-proliferative and counteradhesive protein.
1.3.4 Interaction of SPARe witll growth factors and cytoklnes
Binding to cytokines is one of the major characteristics of SPARC. SPARC
regulates the activity of at least three growth factors that are important for vascular
homeostasis. SPARC was shown to bind the PDGF (platelet derived growth factor)
dimers AB and BB, but not AA. PDGFs are a family of growth regulatory molecules
capable of inducing directed cell migration, proliferation and altered cellular
metabolism. The specific interaction of SPARC with the B-chain prevent binding of
PDGF to its receptors on smooth muscle cells. The affinity of SPARC for this
important growth factor could regulate the availability of PDGF dimers and thus affect
the biological response to PDGF and may consequently control proliferative repair
processes. (Raines, Lane et al. 1992) SPARC interaction with PDGF and its ability to
inhibit cell proliferation induced by PDGF indicate the importance of SPARC in
angiogenesis III. Because both SPARC and PDGF are found in platelet granules, and
expression of both proteins is elevated in atherosclerotic plaque and in models of
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kidney disease, it has been proposed that SPARC might regulate the activity or
distribution ofPDGF in vivo 112. In addition to PDGF, VEGF, and bFGF, SPARC can
also modulate the activity of TGF-j3. TGF-j3 is an important and widely-distributed
growth factor, which is associated with the rapid remodeling of connective tissues and
has been shown to regulate the expression of extracellular matrix proteins 113 SPARC
can upregulates TGF-Bl expression (mRNA and protein) in cultured mouse mesangial
cells 114 SPARC-null mesangial cells also showed significantly decreased synthesis of
TGF-B1 mRNA, and addition of SPARC to SPARC KO cells in culture restored the
expression ofTGF- B to levels typical ofWT cells 114. Given the coincidence ofTGF-
Band SPARC in embryonic development and wound healing 115 the modulation of
SPARC by TGF-B and that of TGF-B by SPARC are likely to be significant. By
contrast, TGF-B had been shown to regulate the expression of SPARC in fibroblasts
116. Whether TGF-B and SPARC interact directly or not is unknown, but it is clear that
both factors participate in a feedback loop that influences their production. There is
considerable circumstantial evidence to indicate that SPARC interacts with TGF-B
and/or affects proteins of the TGF-B signaling pathway.
1.3.5 SPARe as master stroma regulator
Because of its ability to promote collagen assembly and deposition, SPARC is
now considered a key stroma regulator in both tumors and fibrotic diseases. By using a
bone-marrow transplantation (BMT) strategy, Sangaletti et al 117, have demonstrated
that SPARC helps organize the basement membrane structure that is required for tumor
progression. Mammary carcinoma cells that express high levels of SPARC grow into
solid tumors in WT mice. These tumors have a well-structured stroma that comprises
collagen type IV. In Spare-null mice, however, the same tumors grew much more
slowly. Tumors were smaller and less vascularized, contained necrotic areas and were
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devoid of collagen type IV-positive structures such as basement membranes of tumor
lobules and blood vessels. So, SPARC production by the tumor environment, rather
than the cancer cells themselves, is required for tumor progression. In this paper
Sangaletti et al. also showed that when SPARC-expressing bone-marrow cells were
transplanted into null mice, tumors grew at the same rate as those in WT mice. The
transplanted bone-marrow-derived leukocytes localized to the tumors, where they
expressed SPARC, allowing the tumor to develop a well-organized stromal
compartment. Finally, the different immune cell infiltration characterizing tumor from
wt or Spare-null mice have also suggested that the lack of SPARC production in the
tumor environment beside preventing proper basement-membrane assembly might also
protect the tumor from immune-cell infiltration. This finding together with the
increased contact-hypersensitivity response in Spare-null mice 118 characterized by thin
collagen in the dermis, prompted the hypothesis that a different ECM composition
might induce a different immune response. The immune modulatory role of the ECM
and of SPARC was also investigated in melanoma. By injecting human melanoma cell
lines in nude mice in which SPARC expression was knocked down using an antisense
RNA or shRNA led to tumor was rejected through a mechanism PMN dependent 119.
Loss of SPARC expression in melanoma cancer cell lines induced PMN recruitment
and tumor rejection through a mechanism that involved the release of chemotactic
factors like IL-8 and leukotrienes 120. In the context of pulmonary fibrosis, Sangaletti et
al. demonstrated that SPARC distinctly regulates inflammation and collagen deposition
depending on its cellular origin. Reciprocal Spare-null and WT bone marrow chimeras
revealed that SPARC expression in host fibroblasts is required and sufficient to induce
collagen fibrosis in a proper inflammatory environment. Accordingly, Spare-null> WI
chimeras showed exacerbated inflammation and fibrosis due to the inability of Spare-
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null macrophages to downregulate tumor necrosis factor production because of
impaired responses to tumor growth factor-B. The use of bone marrow cells expressing
a dominant-negative form of tumor growth factor-B receptor type II under the
monocyte-specific CD68 promoter as a decoy, phenocopied Spare-null donor chimeras
pointing to a dual role of SPARC in oppositely influencing the outcome of fibrosis 121.
Such a dual role of SPARC has been observed in bone-marrow fibrosis 122. In this
setting, Tripodo et al. have demonstrated that SPARC contributes to the development
of significant bone marrow fibrosis in a model of thrombopoietin-induced
myelofibrosis. They found that SPARC deficiency in the radioresistant BM stroma
compartment impairs myelofibrosis but, at the same time, associates with an enhanced
reactive myeloproliferative response to thrombopoietin. In agreement with these with
this pre-clinical data in humans, SPARC has been implicated in the pathogenesis of
several fibrotic disorders, such as adipose tissue fibrosis, hepatic fibrosis 123, lung
fibrosis, 124, scleroderma or myelofibrosis where the degree of SPARC expression in
BM stromal elements, including CD146+ mesenchymal stromal cells, correlates with
the degree of stromal changes, and the severity of BM failure 122. Fig.l.3.5 summarizes
the involvement of SPARC in stroma regulation.
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Fig.1.3.5 SPARC acts as a master stroma regulator.
SPARC stromal deficiency is responsible to increase BM-fibrosis in a experimental setting of
myelofibrosis TPO-induced; on the contrary the absence of SPARC in stromal cells protect
mice from Bleomycin-induced fibrosis; N2C mammary cells tumor composition injected
respectively in wt and SPARC KO mice, SPARC KO mice present a defective Collagen IV
deposition in tumor stroma.
1.3.6 Role of SPARC in tumor progression
Most of the well-known biological properties of SPARC come from in vitro
studies but the implication of such observations in vivo and, in particular, the in vivo
role of SPARC are not completely understood and frequently studies on SPARC and
cancer, both in murine models and in humans, show contradictory results. In general,
SPARC has been associated with advanced cancer of breast, head and neck, stomach,
prostate and cancer esophagus as well as melanoma and glioma 125,126,127, 119, 120. By
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contrast, ovarian carcinomas show SPARC down regulation associated with tumor
progression 128 while lung and pancreatic adenocarcinomas down regulate SPARC by
promoter methylation during progression 129,130. The reasons for such differences in
SPARC expression are unknown. This complexity arises from the cell-origin and the
fact that SPARC can be produced by tumor and/or stromal cells, although the role of
stromal-SPARC in tumor growth is debated as exemplified in the studies on melanoma
cells. Tumor studies in mice lacking SPARC are also complex as Lewis lung
carcinoma (LLC) cells grow faster 131. These contrasting results have been explained
on the basis of the different types of collagen whose proteolysis generate fragments
favoring or inhibiting tumor angiogenesis in LLC and N2C tumours, respectively,
other mechanisms are likely to be in place. A further complexity in dissecting the role
of SPARC in cancer arisen from experiments in which SPARC has been "artificially"
up-regulated by retroviral or adenoviral infection: such experimental conditions a
condition that could mask the role of SPARC in vivo, since it is known that some
functions of SPARC (e.g. the counter-adhesive one) depend on the amount of SPARC
that is available. Accordingly, in glioma as the ability of SPARC to suppress
proliferation is regulated to a greater degree by the level of SPARC and this
suppressive effect is not influenced by the presence of any of the ECMs. The
oncosuppressor activities of SPARC on ovarian cancer cells are multifaceted and are
attributable to four different SPARC-mediated-effects: 1) SPARC induces apoptosis of
ovarian cancer cells was demonstrated in vitro different ovarian cancer cell lines; 2)
SPARC inhibits integrin-mediated adhesion and growth factor-dependent survival
signaling in ovarian cancer 3) SPARC inhibits mesothelial-ovarian cancer cells cross-
talk; 4) SPARC dampens inflammation in the ovarian cancer microenvironment. By
contrast, SPARC in gliomas and more generally in tumors of the cerebellar system, is
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up-regulated during progression. In such tumors SPARC mediates cellular survival of
gliomas through AKT activation, accordingly the targeting of SPARC expression
decreases glioma cell survival and invasion that is associated with reduced activities of
FAK and ILK kinase. This aspect has been related to the capability of SPARC to
promote integrin clusters on the cell surface and to stimulate signaling. Such an effect
is in contradictory with SPARC effect on ovarian cells. It would be interest to
understand the reasons why these opposing effects occur.
Fig.1.3.6 SPARC throughout tumor progression.
SPARe affects tumor progression at different levels; in malignant transformation during the
early development stage; later on, SPARe is expressed both by tumor cells and stromal cells
skips tumor immunity and regulates tumor escape
1.3.7 Role of SPARC in autoimmunity and associated transformation
Numerous studies have linked so far several different autoimmune disorders, or
chronic inflammatory conditions, with benign lymphoproliferation or malign
lymphoproliferation. The disregulation of immune cells that occurs in these conditions
depends on not only defects that are intrinsic to the immune cells (like germline or
somatic mutations) but also on defective signals coming from stromal cells in the
tumor miroenviroment. In addiction to prosurvival factors for resting Band T cells (i.e.
Baff, April) stromal cells of secondary lymphoid organs also produce insoluble factors
like ECM molecules and SPARC. The finding that ECM molecules like collagens and
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fibronectin are regulatory ligand for immune cells, including B cells, prompted the idea
that the ECM and ECM-regulatory proteins might play a role in the maintenance of
SLO homeostasis and its defective remodeling also in secondary lymphoid organs
(SLO), for example related to the absence of SPARC, associated to autoimmunity and
lymphomagenesis. To test this hypothesis Sangaletti et al 21 in our laboratory
established an ad hoc murine model by crossing autoimmunity-prone Fas mutant (lpr-
Ipr) mice to Spare-null mice. Fas mutant mice, similar to the human counterpart,
develop an autoimmune lymphoproliferative disease characterized by lymph node and
spleen enlargement, auto-antibodies accumulation and increased risk of developing
lymphomas. Similarly to human carrying a Fas mutation the penetrance of this
phenotype in Ipr-Ipr mice is not 100% in agreement with the hypothesis that Fas
mutation might operates in a background of other genetic or environmental influences.
Sangaletti et al. demonstrated that autoimmunity associated with Fas mutation was
exacerbated toward lymphomagenesis due to SPARC lack. The absence of SPARC
resulted in defective collagen assembly, with uncompartmentalization of lymphoid and
myeloid populations within secondary lymphoid organs (SLO), and decreased
inhibitory signals from the ECM. These conditions promoted unforeseen interactions
between neutrophil extracellular traps (NET) and CD5+ B cells that underwent
malignant transformation due to defective apoptosis under the pressure of neutrophil-
derived trophic factors and NF-kB activation. Interestingly, this model of defective
stromal remodeling during lymphomagenesis correlates with human lymphomas in a
SPARC-defective environment, which is prototypical of CD5+ B cell chronic
lymphocytic leukemia (CLL).
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Fig 1.3. 7 Schematic model oj SPARe regulation oj autoimmunity to lymphoma
transition.
SPARC deficiency in a model of based Fas-mutated gene causes defective collagen deposition
with an increased infiltration of myeloid cells. These conditions promoted unintended
interactions between myeloid cells and the lymphoid clone and decrease the inhibitory signals
mediated by LAIR-Ion MDSC activation. This condition regulated by SPARC is associated to
an increased NETosis induced in PMN that lost their antiapoptotic signals impaired tolerance
and enhance autoimmunity responses. In this condition CD5+ B cells proliferation is
determined which underwent malignant transformation due to defective apoptosis under the
pressure of neutrophil-derived trophic factors and NF-kB activation. Furthermore, this model
of defective stromal remodeling during lymphomagenesis correlates with human lymphomas
arising in a SPARC-defective environment, which is prototypical of CD5 + B cell chronic
lymphocytic leukemia (CLL) in periphery and a SLE-like condition in dLNs. Picture is adapted
from Sangaletti et al. Cancer Discov. 2014 Jan;4(J):11O-29.
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2. MATERIALS AND METHODS
2.1 Materials
2.1.1 Mice and tumors
In vivo Doxil efficacy, tumorigenicity and the analysis of in vivo EMT features
of transpantable tumor models were assayed in Spare +1+ (BALB/c) and Spare" mice
injected s.c. into the mammary fat of the inguinal region with the cells at a
predetermined maximal non-lethal dose. BALB/c and Spare" female mice of 8 to 10
weeks old were used. BALB/cAnNCrl mice were purchased from Charles River
Laboratories (Calco, Italy). Spare" mice were provided originally by C. Howe (The
Wistar Institute, Philadelphia. PA) on a mixed 129SV/ C57BLl6 background and were
backcrossed afterwards for 12 generations with BALB/cAnNCd (Charles River
Laboratories) in order to obtain congenic Spare": mice. Spare" mice used in this study
are maintained on a BALB/c background. Tumor take and volume were monitored
twice per week. Tumors were measured with calipers in the two perpendicular
diameters, and tumor volume (mrrr') was calculated as longest diameter x (shortest
diameterr', To derive primary mammary carcinoma cell lines, spontaneous mouse
model of mammary carcinomas BALB-neuT mice and SPARC-neuT were used.
BALB-neuT mice are transgenic for the activated form of the rat c-erB2 oncogene and
develop mammary tumors involving all mammary glands 132. SPARC-neuT mice were
derived from BALB-neuT mice that were back-crossed with Spare" mice.
Mice were bred and maintained at the Istituto Nazionale Tumori under standard
conditions according to institutional guidelines.
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2.1.2 Cell lines
Primary mammary carcinoma cell lines (SN25A, SN25D, SN25E) were
derived from female SPARC-neuT mice. N3D (inguinal) primary mammary carcinoma
cell lines were derived from female BALB-neuT mice. Tumors were removed and, in a
sterile environment, cleaned of fat, large vessels, and necrotic areas, minced with
scissors, and placed in warm trypsin (37 C for 30 min). After washing with DMEM
(GIBCO) and the addition of 10% heat-inactivated FCS (Bio Whittaker), tissue was
passed through strainers and washed again. Cells were counted and seeded in 6-well
plates at 0.4 106cells/ml in DMEM plus 20% FCS. Mammary carcinoma cell lines that
were unable to produce SPARC (SN25A, SN25E, SN25D) were infected with the
retroviral vector LXSPARCSH and forced to express SPARC expression. SPARC
expression has been analyzed by Western blotting using a specific rat a-mouse SPARC
mAb as described in the Section 2.2.8. The most stable clone SN25A and its co-
isogenic transduced counterpart (SN25ASP) were selected and were used for the
majority of the experiments herein presented. Key experiments were confirmed using
N3D and N3DSPARC pair obtained through infection with the same LXSPARCSH
retroviral vector as the N3D w-t counterpart. Parental cell lines were maintained in
monolayer cultures in Dulbecco's modified Eagle's medium (DMEM) (GIBCO)
supplemented with 10% fetal bovine serum (FBS). Cells were maintained at 37°C
humidified atmosphere with 5% C02. Transduced stable clones were maintained in
DMEM plus 10% FBS added 600 ug/ml Hygromicin dissolved in PBS 1% provided by
(Santa Cruz). To establish the effects of tumor-derived SPARC, the above cell lines
were compared with their wildtype counterparts. A possible experimental bias could
be caused by SPARC anti-proliferative effect 133, therefore, transduced cell lines
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selected for intermediate expression (similar to that of spontaneous tumors) were used
for the injection into a Spare +1 + and Spare" mice.
2.1.3 Antibodies used
Specificity-
Antibody
Clone-brand Diluition Incubation
Byotinalated Ly6G and
Ly·SC
Polyclonal iNOS antibody
BD. Ebloscence 1:50
The monoclonal antibody RB6-8CS reacts strongly with
neutrophil-specific ly6G Ag. but it has also been
described to cross-react with the Ly6C Ag.
Cayman Chemical 1:1000
Purified enzyme from mouse macrophages
(RAW264.7) cells
1h RT
1 h RT
Polyclonal Cox-2 (Cyclo·
oxygenase-2antibody)
AeRIS antibdodies 1.50
Purified Rabbit Ig anti Ms and Hu
1 h RT
iNOS Polyclonal Antibody
BD, Pharmlngen 1: 100
The purified JESS-2AS antibody (Cat. No. 551215) is
useful as a capture antibody for a sandwich ELISA for
measuring mouse IL-ID protein levels.
Cayman Chemical 1.1000
Purified enzyme from mouse macrophages (RAW
264.7) cells.
1 h RT
Purified Mouse antl·ll-10
1 h RT
Table.S Antibodies used jor IHC analysis
2.2 Methods
2.2.1 Doxil treatment
To assess chemotherapy sensitivity in vivo, and to avoid cardiotoxicity and
improve transcytosis, "Doxil" (Doxil, a Pegylated form of Doxorubicin) Caelyx
2mg/ml (Sterling A) was used134,135. 1*106 SN25A and SN25ASP tumor cells were
injected in the mammary fad pad of 8 old-week (Spare +1+) BALB/c mice (Charles
River Laboratories, Wilmington, MA) (n=20) and Spare" BALB/c mice (n=20),
generated as described in Section 2.J.1, and when tumors reached a volume of
approximately 20 mrrr' (day 15), animals were randomized into treatment groups. Mice
were then either given 10 mg/kg of Caelyx twice, i.v., on day 15 and 30, or left
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untreated as control. Tumor sizes were measured by a caliper 2 days per week and
recorded as tumor volume calculated as longest diameter x (shortest diameterr'.
Growth was monitored for 40 days from tumor injection. Mice were sacrificed when
tumors in control mice reached a volume of 1 cm3. At day 40, Doxil efficacy,
estimated as % of tumor volume was calculated by the formula (Mean tumor volume
(MTV) untreated-MTV treatedlMTV Untreated*100).
2.2.2 Doxil plus Zometa treatment
BALB/c female were subcutaneously injected with 1*106 of SN25ASP tumor
cells. When tumors reached 20mm3 size, mice were randomized into different groups.
Beginning on day 15 after tumor cell injection, mice were treated with Doxil (10
mg/kg body weight via i.v. as described above in Section 2.2.1, Zometa (lOO ug/kg
body weight s.c.), Doxil plus Zometa, Doxil followed 30 min later by Zometa 136 (n =
20 mice per group).
2.2.3 Zometa treatment
Zoledronate (Zometa; Novartis Europharm, Ltd.) at a dose of 0.1 mg/kg was
diluted in saline and administered daily s.c. 5 days a week. Mice were weighed weekly,
drug concentration was adjusted to their actual weight. Mice were monitored for tumor
growth, EMT and the expansion of MDSC in the peripheral blood was also evaluated.
EMT features were evaluated after treatment, when tumors reached a volume of 600
mm'.
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2.2.4 Celebrex treatment
Anti-Cox-Z inhibitor, used for in vivo study, was provided by Novartis as 200
mg capsules (Celebrex). The content of each capsule was dissolved in DMSO to a final
concentration of 25 mM. To test the role of COX-2 in vivo, BALB/c mice were
injected with SN25ASP tumor cells. Starting on day 15 after tumor injection, animals
were treated with COX-2 inhibitor (5 mg/kg) or vehicle control (DMSO) every other
day in the contralateral side of the tumor. Mice were monitored for tumor growth twice
a week. EMT and MDSC expansion in the peripheral blood were also evaluated. To
establish the efficacy of the Doxil plus Celebrex combined treatment, drugs were
administrated simultaneously, each according to its schedule.
2.2.5 Histopathology and IHC
Tumors were harvested for morphologic analysis and embedded in paraffin.
Sections of 3 to 4 urn thick were cut from paraffin blocks and stained with H&E
(SIGMA-Aldrich) for the evaluation of in vivo EMT features; Masson's trichrome
(SIGMA-Aldrich) for Collagen distribution quantification; Gomori Trichrome for
detection of interstitial fibers. Analysis included 15 cases per condition. For the
evaluation of lung metastasis, lungs were removed from mice after sacrifice and were
fixed in situ by intratracheal injection of 10% neutral buffered formalin. The trachea
was canulated and the lungs fixed in situ with 10% formalin at a constant rate. The
optimal instilled volume for mouse lungs was 0.3 mL for 20 g of weight. Lungs were
removed, maintained 24 hours in formalin, and then embedded in paraffin. Sections of
3 to 4 urn thick were cut from paraffin blocks and stained with H&E. To characterize
infiltrating immune cells, IHC analysis was performed on OCT sections. For
immunohistochemestry, 5- u m cryostat sections were fixed in acetone and incubated
for 1 h with the reported Abs. After antibodies incubation, sections were washed and
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overlaid with biotynilated goat anti-rabbit IgG for 30 min and with avidin-peroxidase
complex for 30 min. A list of antibodies used is showed in Section 2.1.3. Avidin-
peroxidase complex was used as secondary antibody to detect sections incubated with
biotinylated primary antibody. Cox-2 immunostaing reactivity was revealed with
alkaline phosphatase (LSAB+ kit AP, Dako Denmark) method. Sections were
counterstained with Mayer's hematoxylin, dehydrated in graded alcohol (70%, 95%,
and 100% ethanol), and mounted in BDH mounting medium (Merck Eurolabs). The
immunostaining of IL-lO in SN25A and SN25ASP tumors was performed by
intracellular staining of cytokines. Tumors, embedded in OCT compound were fixed
with 2% of paraform-aldehyde for 20 min and then washed. Sections were incubated
sequentially with a blocking and a permeabilization buffer both made in PBS (1%
bovine serum albumin; 0.1% saponinll% FCS, respectively). Subsequently, sections
were incubated with avidin-biotin blocking solution (Vectashield) for 15 min and
finally they were incubated overnight with a rat anti -IL-lO, (see Section 2.1.3 for
datasheet informations). The following day, sections were washed with PBS 1%v/v
and incubated with secondary antibodies provided by DAKO and revealed as
previously described. Immunostained sections were evaluated under a NIKON El 000
invert epifluorescence miscroscope optical microscope using 20x (numeric aperture
0.4) and 40x (numeric aperture 0.65) objective lenses.
2.2.6 Immunofluorescence and laser confocal microscopy
Immunofluorescence analysis of EpCAM and B-catenin expression was
performed on SN25A and SN25ASP mammary tumor cell lines. Cells were seeded at
approximately 2*105cells/35 mm poly-d-lysine coated glasses. Cells were fixed with
4% PFA, subsequently permeabilized with Triton-X-I00 (0.1%) and incubated in
blocking buffer (10% v/v FBS in PBS). Cells were re-hydrated in PBS and incubated
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for 1h with a primary antibody. Cells were then washed in PBS and incubated for 30
min with the appropriate goat Alexa Fluor 488/546 antibody (I :500; Invitrogen,
Probes, eugene, Oregon). Primary antibodies used were rabbit anti-mouse CD326
(EpCAM) antibody purified G.8.8 (1:100; BD elliosciences); rabbit anti-mouse B-
Catenin mAb (1:100; Sigma-Aldrich, St. Louis). Nuclei were stained with 4',6-
diamidino-2-phenylindole. Slides were mounted with Prolong anti-fade reagent (Life
Technologies, Monza, Italy) and examined under a RADiance-2000 (Bio-Rad, Milan,
Italy) Nikon-TE300 laser scanning confocal microscope (Nikon Instruments S.p.A,
Florence, Italy). Images in .tif format were analysed with ImageJ as single chanel and
then merged with Photoshop CS4 EXTENDED version 10.0.
2.2.7 Flow cytometry analysis
FACS analysis were performed on PBMCs (Peripheral blood mononuclear
cells), BM (bone marrow) and SPL (spleen) in order to assess the frequency of
circulating Ly6GhighLy6CIOWCD11b+ myeloid cells subsets. The frequency and
distribution of myeloid progenitors (Lin-cKit; LK), including common myeloid
progenitors (CMP), granulocyte-macrophage progenitor (GMP), and
megakaryocytic/erythroid progenitor (MEP) was also evaluated. Analysis of
circulating MDSC was performed collecting blood samples from retroorbital sinus and
mixed with equal volume of 5 mmol/L EDTA, erythrocytes were lysed by hypotonic
shock in NH4Cllysis buffer. After that, cell suspension was centrifuged at 300 g for 5
min and washed twice with PBS containing 2% fetal bovine serum (FACS buffer).
Finally, cells were blocked with 10 u g/mL of rat anti-mouse CDI6/CD32 Ab (clone
2.4G2; BD PharMingen) before staining with the combination of antibodies: Rat anti-
mouse PerCP-CY5.5-Conjugated CDIIb (MI-70), Anti-Mouse Ly-60 (Or-I) FITe
(RB6-8C5) and APC-conjugated rat anti-mouse Ly6C in FACS buffer. SPL and BM
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samples were cut in small pieces and processed with a 0.5 ml syringe in sterile
conditions. Suspensions were filtered by a cell strainer (BD, Franklin Lakes, NJ). After
that, cells were washed, re-suspended in 1x PBS, and stained with the indicated
monoclonal antibodies. To prevent nonspecific binding, Fe Blocker (anti-mouse
CD16/32, BioLegend) was added to single cell suspensions for 5 min on ice and then
stained with a pool of antibodies for lineage (Lin)-positive markers, including CD3,
CDllb, CD45R, Ly6G, CD4, CD8, Ter-1l9 (all PE-conjugated) and stem cell and
progenitor cell markers, including CDl17 (FITC-conjugated), CD34. (APC-
conjugated), all purchased from eBioscience. In vitro evaluation of EMT features was
performed by FACS analysis. 6 well cultured SN25A, SN25ASP, N3D and
N3SPARC, N2C cell lines (used as positive control) were gently detached and single
stained for 60 min at room temperature with primary antibodies. To dectect N-CAM
and integrin Bl , polyclonal rabbit antibody specific for anti-mouse N-CAM (AbCAM).
rat antibody for integrin B1 (CD29) (clone HMB 1-1; Biolegend), anti mouse APC-
conjugated EpCAM (CD326) (clone G8.8; eBioscience) were used. Primary antibodies
were delivered with the following antibodies: a anti-Rbt FITC conjugated and anti-Rat
antibody PE conjugated used 1:200. All the primary antibodies were diluted in PBS for
cell surface staining or in saponin buffer 0.2% saponin and 0.5% bovine serum
albumin (Sigma-Aldrich) for intracellular staining. Isotype-matched IgGs were used as
controls. All samples were purchased by FORTESSA (Becton Dickinson) and data
were subsequently analyzed using Flowjo 9.4.10.
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2.2.8 Western blot analysis
Cells were collected in the eppendorf or falcon, centrifuged at 335 g for 15 min
at RT. Cells were lysed in a RIPA buffer containing 50 mM Tris, PH 7.4, 1% NP-40,
150 mM NaCI, 1 mM EDTA, 1 mM Na3V04 and protease inhibitor cocktail (Roche).
Proteins were separated by SDS-P AGE and subjected to immunoblotting. Celllysates
were microcentrifuged at 14,000 x g for 20 minutes at 4°C and supernatants collected
and stored at -80°C. Protein concentration in each sample was determined by the
BCATM Protein Assay kit (Thermo Fisher Scientific, Waltham, MA). Cell lysates
containing equal amounts of protein (25 J.l g) were analyzed by SDS-PAGE on precast
minigels (Invitrogen. Carlsbad. CA) and proteins were transferred to a nitrocellulose
membrane (GE Healthcare, Waukesha, WI). Nonspecific binding sites were blocked in
5% non-fat dry milk in Tris-buffered saline-Tween (lOO mmollL Tris, 0.9% NaCI, pH
7.5,0.1% Tween 20) solution. For the detection of SPARC expression in tumor cells,
membrane was incubated overnight at 4°C with a polyclonal antibody to SPARC
(R&D), washed three times each for 5 minutes with Tris-buffered saline containing
0.1% Tween 20, and then incubated with horseradish peroxidase-conjugated antibody
(1:2500; Zyrned, San Francisco, CA) for 1 hour at room temperature. For western blot
analysis of TNF -a and TGF -13 expression in macrophages culture, 1'"106 differentiated
Spare +1+ and Spare" macrophages were cultured in a 6 well. Equal amounts of total
protein (25 ug) were loaded in each lane. Blots were blocked and incubated overnight
at 4°C with a monoclonal rat anti-mouse TNF-a antibody (Becton Dickinson) and with
an anti-TGF-B Functional Grade Purified (clone IDl1.16.8). After washing, blots were
developed with an enhanced chemiluminescence system (ECL-plus; GE Healthcare).
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2.2.9 MMT proliferation assay
To test proliferation of tumor cell lines in vitro proliferation, cells were plated
into 96-well V-bottom microplates (Nunc, Denmark) at a density of 1* 106 cells/ well
in 200 ul ofDMEM medium supplemented with 10% FBS and cultured for 1,3, 7 days
selected as the experimental time point (t=s). Tumor cells viability was assessed by
incubating tumor cells with MTT solution (5 mglmL Thiazolyl blue Tetrazolium
Bromide) for 4h at 37° C (Sigma). After incubation, crystalized MMT solution was
dissolved in 100 of dimethyl sulfoxide (DMSO), and measured at 590 nm using an
ELISA reader. The ratio of cell proliferation was calculated as (OD mean t=O/OD
mean t=s).
2.2.10 Cytotoxicity assay
In vitro the efficacy of Doxil was tested for SN25A and SN25ASP cell lines
using the previously described colorimetric MMT assay. Cells suspensions were
dispensed into different 96 U-bottom well (as described in Section 2.2.9) one for each
evaluated time point, and incubated for 24 h at 37°C in a fully humidified atmosphere
of 5% C02. Then Doxil to final concentration of 5 J1, M) was added in a volume of 200
J1, 1. Tumor cells inhibition mediated by Doxil was evaluated 6, 12, 24, 48 h after
treatment. Results were measured using an ELISA plate reader as previously described
(Section 2.2.9). The cytotoxic/cytostatic effect of doxorubicin was calculated as % of
tumor cells Doxil inhibition was calculated by the formula (experimental absorbance-
background absorbance)/ (absorbance of untreated controls-background absorbance) x
100.
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2.2.11 Enzyme-Linked Immunosorbent Assay (ELISA).
To quantify the amount of GMCSF and GCSF, cells were seeded at a ratio of
1:1 (106 cell/10 ml) in a 96 well-plate and cultured. The supernatants were collected
after 48 h. Quantification of mouse GMCSF levels was performed using a BD
OptEIATM kit (Cat#555167) specific for mouse GMCSF. For the quantification of
GCSF levels, a Ray Biotech (Cat#: ELM-GCSF-OOI) G-CSF ELISA Kit specific for G-
CSF was used. To quantify serum levels ofMMP-9 and VEGF in tumor- bearing mice
recipients of the adoptive transfer, a specific ELISA Kit that detects total levels of
MMP9 was purchased from R&D (Cat#Kit- MMPT90) while for VEGF (isoforms A-
B) a specific kit was purchased from Peprotech (Cat# 0608099) was used. Results are
reported as mean ofOD values ±SEM.
2.2.12 Isolation andfunctional characterization of splenic and tumor-derived
MDSCs
2.2.12.11solation of splenic MDSCsfor RNA preparation
G-MDSC (CDllb+Ly6GhighLy6CIOW) and M-MDSC
(CDllb+Ly6GIOWLy6Chigh) were isolated from the spleen of tumor-bearing mice
through immunomagnetic separation using a specific kit obtained from Miltenyi
(Myeloid derived Suppressor Isolation kit; MACS ®). The purity of G-MDSC and M-
MDSC populations were checked by FACS analysis by using a mixture of the
following antibodies: PerCP-CY5.5-Conjugated anti-mouse CDllb (MI-70); FITC-
conjugated anti-Mouse Ly-6G (Gr-1) (RB6-8C5); APC- conjugated Ly6C anti- mouse
(clone HK1.4).
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2.2.12.2 Cell sorting of tumor-derived MDSC
MDSC and their subsets were isolated from tumors of tumor-bearing or control
mice using cell sorting on FACSAria cell sorter (BD Biosciences). The purity of cell
populations was >99%. For isolation, tumor tissues were cut into small pieces and
treated with collagenase (type IV, 1 mg/ml, Sigma-Aldrich) and Elastase (6U/ml,
Sigma-Aldrich) for 45 minutes at 37°C, and dead cells were removed by centrifugation
over a Ficoll-Hypaque gradient (Atlanta Biotechnology). Cell suspensions were stained
with the following mixture of antibodies: PerCP-CY5.5-Conjugated Rat anti-mouse
CDIlb (MI-70); Anti-Mouse Ly-6G (Gr-I) FITC (RB6-8C5) and APC-conjugated rat
anti-mouse Ly6C (clone HK1.4).
2.2.12.3 RT-PCRfor TaqMan probes based Real Time PCR (qPCR)
For quantitative RT-PCR, myeloid cells were lysated with Trizol (Invitrogen
Life Technologies) and RNA was extracted by using RNeasy Kit (Qiagen, Valencia,
CA). Traces of DNA were removed by treatment with DNase I. The cDNA was
synthesized from I ug total RNA according to the manufacture protocol of Kit Applied
Biosystems. RNA was retrotranscribed with a kit provided by Invitrogen (18021-071).
2.2.12.4 Quantitative real-time PCR
PCR was performed using Taqman Universal PCR master mix (Applied
Biosystems, Foster City, CA, USA) and target gene assay mix containing sequence-
specific primers for ARG-I, CCL2, CCL5, COX-2, NOS-2 genes. Gene-specific primers
(all 5'-3' direction) were purchased from Applied Biosystems (Cel2, Ref. Seq.
NM_OII333.3; CelS Ref Seq.NM_OI3653.3; Stat3 NM_Ol14886.4; ARGI
NM_000036.2; Nos-2-iNOS NM_OI0927.3; PTGS2 (COX-2) NM_Oll1983). The
reaction was set according to the standard TaqMan qPCR conditions reported in the
Applied Biosytem protocol, and was performed in duplicates for each samples. The
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qPCR reactions were run using ABI PRISM ® 7900 Fast Real Time PCR system and
ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems) and analyzed
with SDS Software 2.3 (Applied Biosystems). The target gene mRNA was quantified
by measuring CT to determine the relative expression. Results have been reported
using the fold change in the target gene expression of the target genes relative to the
internal control gene (GAPDH).
C Id h . . I I d 2-MCT hThe mean 10 c ange m target gene expression was ea cu ate as were
~~CT=«Cf,Target CT,GAPDH)sample-(Cf,Target er ,GAPDH)intemal
2.2.13 In vitrofunctional characterization of MDSC phenotype
2.2.13.1 In vitro suppression assay.
In vitro suppression assay was performed by using total CDII b+Ly6G+Ly6C+
myeloid cells without separating them in the two subsets (G- and M-MDSC). Myeloid
derived suppressor cells were purified using CDII b-conjugated microbeads and
Myeloid-Derived Suppressor Cell Isolation Kit (both from Miltenyi Biotec) following
the manufacturer's instructions. In vitro T cell suppressive activity was measured,
labeling 4 x 105 natve BALB/c splenocytes with CFSE (Carboxyfluorescein
Succinimidyl ester; SIGMA Aldrich) and co-culturing them with the MDSCs.
Different concentrations of MDSCs (1xI04 to 5 x 104) were cocultured with a fixed
concentration (1x ] 04) of activated splenocytes for 72 h in complete medium containing
RPMI 1640 (Sigma-Aldrich) supplemented with 5% FCS, 2 mM L-glutamine, 200 U
penicillin, and 200 mg/ml streptomycin (Sigma-Aldrich). Each sample was seeded in
triplicate. Total splenocytes were stimulated with 2 mg/ml of soluble anti-CD3 and I
mg/ml of anti-CD28 added to medium or left unstimulated as negative control.
Proliferation of CD4 and CD8 T cells has been assessed 2 and 3 days later, by and
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evaluating CFSE dilution in the CD4+ and CD8+ gated populations. Results are shown
as percentage of proliferated cells (mean±SEM).
2.2.13.2 Cytostatic assay to test antitumor activity of PMNs
To test antitumor activity of PMNs (Polymorphonuclear leukocytes) in tumor
cells, conditioned PMNs were isolated using agar plugs method. Blocks of 2% agarose
and 0.2% gelatin in saline (agar plugs) were implanted in Spare +1+ and Spare" mice
and after 5 days, agar plugs were removed and PMNs were collected by washing 3
times agar blocks with IMDM supplemented with 10% of FCS (GIBCO, Life
Technologies). 70%-75% of these cells are PMNs that are enriched up to the 95% after
30 minutes of adherence on plastics. In some cases, naive PMNs were obtained
through immunomagnetic cell separation from spleen using a specific kit (anti-Ly6G
MicroBead Kit, Miltenyi). Cytostatic activity of PMN was evaluated in a
spectrophotometric assay. Briefly, tumor cells (SN25A and SN25ASP cell lines) (104)
were incubated with PMNs in a float-bottom coated 96-well (Costar, Cambridge) using
12:1 to 100:1 ratios of attached cells (PMNs) to target cells (tumor cells). 72 h after
incubation, culture wells were fixed with 5% formalin and stained with 1% methylene
blue in 0.01 M borate buffer, pH 8.5. After eluting the dye from cells with 0.1 N HCI,
absorbance was read at 620 nm. The percentage of growth inhibition was calculated as
[1 -(A-B-C)/(D-C)], where A= absorbance in cultures of tumor cells and PMNs;
B=PMNs alone; C=104 tumor cells after 2h adhesion; D= dye alone. Results are
presented as mean of OD values (±SD) of six replicates.
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2.2.13.3 Coculture experiments
Lineage negative cells were obtained from BM through negative selection by
using a specific kit, Lineage Cell Depletion Kit (MACS, Order No. 130-090-858).
Lineage negative cells (l05 cells) were seeded directly onto a monolayer of tumor cells
(SN25A and SN25ASP cell lines) or in the presence of a Transwell (0.4 u m pore size
from Coming LifeSciences) to ensure Lin- cells feeling of tumor-derived cytokines
and avoid cell-to-cell contact. Control Lin- cells were cultured in the presence of the
following cytokines: rGM-CSF (10 ng/ml), rGSCF (5 ng/ml), rTGF- 81 (10 ng/mL)
(all cytokines/chemokines were provided by R&D). Six days later, cells were
harvested and Lin-cells differentiation towards the different subsets of myeloid cells
was checked by FACS analysis using the following Abs: PerCP-CY5.5-Conjugated
Rat anti-mouse CDIIb (MI-70); Anti-Mouse Ly-6G (Gr-I) FITC (RB6-8CS) and
APC-Conjugated Rat anti-mouse Ly6C. Results were reported as mean percentage of
Ly6GhiLy6C+ and Ly6G1ow Ly6C+subsets gated on CD11b+ cells.
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2.2.14 Adoptive transfer of MDSC in tumor-bearing mice
To directly test in vivo the capability of MDSC to promote EMT and tumor
growth, also according to their Spare genotype, tumor bearing Spare" mice
(SN25ASP) were i.v. injected with 106myeloid cells isolated from the spleen of donors
mice. As donors, we used Spare +1+ and Spare" mice, previously injected with
SN25ASP tumor cells (40 days before, a condition that ensured the presence of tumors
and subsequent MDSCs expansion). The adoptive transfer was performed once a week
for 4 consecutive weeks using a tumor size of 8 mm3 in recipient mice as a starting
point. Mice adoptively transferred with MDSCs were checked for tumor growth,
VEGF and MMP9 serum levels. At endpoint, tumors were harvested and histologically
analyzed for aggressiveness and EMT.
2.2.15.ln vitro macrophage preparation
Spare +/+ and Spare -/- macrophages were obtained from bone marrow
precursors by plating them in the presence of 10 ng/mL of granulocyte-macrophage
colony-stimulating factor (GM-CSF) and 10 ng/mL of IL-4. On days 2, 4, and 6,
floating cells mainly consisting of dendritic cells were eliminated and supplemented
medium was replaced. On day 7, up to 90% of the adherent population consisted of
macrophages as determined by flow cytometry analysis using the F4/80-specific
monoclonal antibody (Caltag-Medsystems, Buckingham, UK).
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2.2.16 Detection of intracellular cytokines in activated macrophages
Sparc'" and Spare" macrophages were seeded at 2*105 cells/well on 96 well
and cultured for 24 h. To detect intracellular cytokines production, macrophages were
stimulated with 50 ng/ml PMA, 500 ng/ml Ionomycin (SIGMA-Aldrich) and
Monensin (eBioscience) for 4 h at 37°C, fixed in FixlPerm buffer (eBioscience) and
stained for a mAb TNF-a APC conjugated antibody and FITC conjugated mAb F4/80
(Ebioscience).
2.2.17 Statistical analysis
Statistical analysis of single treatments (Celebrex or Zometa) was performed
usmg the Mann-Whitney test. Significance of different combined treatments was
assessed with one-way Anova with Dunn's Multiple Comparison Test. For other
analyses related to MDSC frequency or ELISA data, differences between groups were
tested for significance using a two-tailed unpaired t-test. Values were considered
statistically significant at p < 0.05. All the analyses were performed using Prism
software Version 5.0d (GraphPad).
74
3. AIMS OF THE THESIS
Communication between cancer cells and leukocytes occurs through a complex
network of pro-inflammatory mediators in which the NF-kB pathway is predominant.
Among the ECM proteins induced by remodeling and inflammation, SPARC (Secreted
Protein Acidic and Rich in Cysteine) has been indicated as marker of poor prognosis
and poor response to therapy in independent series of mammary carcinomas analyzed
using expression array technology. Using carcinoma cells from MMTV-HER-2/neu
transgenic mice, we have shown that host-derived rather than tumor-derived SPARC
determines collagen density and leukocyte infiltration of the stroma, thus defining the
lobular structure of mammary carcinoma. This finding, together with the above
mentioned gene array results, prompts the hypothesis that tumor-derived SPARC and
infiltrating inflammatory cells are a major obstacle to chemotherapy and/or biological
therapy. In order to validate this hypothesis, I studied the effect of tumor-derived and
stroma-derived SPARC on the outcome of chemotherapy in transplantable tumor
model of mammary carcinomas.
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4. RESULTS
4.1 SPARe PROMOTES IMMUNE-MEDIATED EMT
4.1.1 Replacing SPARe expression in primary spontaneous mammary carcinoma
eel/lines/rom transgenic MMTV-Her2 mice (BALBNeuT) also SPARe knock-out.
To establish primary mammary tumor cell lines defective for SPARC
expression, MMTV -Her2 Neu (BALBNeuT) 132 were crossed with SPARC-KO mice
to obtain the double mutant (SPARC-NeuT). Inguinal and thoracic tumors were
removed from SPARC-NeuT mice and, in a sterile environment, cleaned of fat, large
vessels, and necrotic areas, minced with scissors, and placed in warm trypsin (37°C for
30 min). After washing with DMEM and the addition of 10% heat-inactivated FCS,
tissue was passed through strainers and washed again. Cells were counted and seeded
in 6-well plates at 0.4 x 106 cells/ml in DMEM plus 20% FCS. Three of these Spare-
deficient mammary carcinoma cell lines, namely SN25A, SN25D and SN25E and the
BALB-NeuT-derived N3D line, characterized for low SPARC expression 138, have
been transduced with the retroviral vector LSP ARCSH to replace or over-express
SPARC, respectively. SPARC expression was then evaluated by Western Blot as
shown in Fig I-A. The most stable SN25A cell line and its co-isogenic SN25ASP
counterpart were selected and key experiments were confirmed with the N3D and
N3D/SPARC pair. SPARC overexpression did not change cell proliferation in vitro of
both SN25SP and N3D/SPARC cell lines compared with their wt counterpart (Fig. IB-
C).
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Fig.1 SPARC-induction has no effect on tumor cell proliferation in vitro.
(A) Western Blot analysis for SPARC expression in SN25A, SN25ASP, N3D, N3DSPARC
cells lines. The N2C murine mammary cell line, previously characterized for high SPARC
expression, was used as positive control (B) Proliferation of SN25A or SN25ASP cells was
measured in vitro through an MTT assay The ratio of cell proliferation for each time point
was calculated as (OD mean t=OIOO mean t=s); (C) the same analysis was performed for
N3D, N30SPARC cell lines at the indicated time points
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4.1.2 SPARC-overexpressing cells, but not the parental cell lines, undergo epithelial-
to-mesenchymal transition in vivo.
To test the role of SPARC in tumor growth and progression, SN25A and SNA25SP
cells were injected into BALB/c mice (106cells/mice) that were monitored for tumor
take and lung metastasis. SN25ASP cell lines showed an impaired growth in
comparison with non-transduced counterpart (Fig. 2-A); Histological analysis (H&E)
of SN25ASP tumors showed the presence of cells with a spindle-like morphology
intermingled with abundant collagen and forming ill-defined nest-like structures, a
typical feature of cells undergoing EMT and similar to that of hurnan ductal mammary
tumors (Fig. 2-B and Fig. 3). In SN25ASP tumors, stromal septa were interrupted and
unable to define the lobular structures. By contrast, the parental SN25A tumors were
composed by epithelial cells organized in lobular structures embedded in a dense
stroma (Fig. 3-A, C, E). Collectively, the histological analyses suggested that
replenishing SPARC expression in tumor cells modifies their behavior in vivo, for
instance promoting EMT. In agreement with the EMT phenotype, SN25ASP tumor
cells were more aggressive and capable of invading the surrounding tissue margins
(Fig. 3-B, D, F) despite the reduction of their mitotic index. The difference between
SN25ASP and SN25A in terms of in vitro proliferation and in vivo tumor outgrowth
was confirmed in the N3D and N3DSPARC mammary cell lines pair. Over-expression
of SPARC in the N3D cell line did not affect their in vivo growth (Fig.4-A) but, as in
the SN25ASP cell line, SPARC promoted a change in tumor grade and acquisition of
spindle-shape morphology of the tumor cells, less-defined lobular structures and
invasion of surrounding tissue margins (Fig. 4-B). Interestingly, N3DSPARC tumors
showed increased collagen content consistent with their mesenchymal phenotype (Fig.
4-D). To confirm that SN25ASP and N3DSPARC, but not the parental counterparts,
underwent EMT, IHC analysis was performed for E-cadherin and N-cadherin
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according to their epithelial and mesenchymal marking, respectively. Parental cell lines
SN25A expressed E-cadherin but not N-cadherin on the cell surface, whereas their
SPARC-transduced counterparts showed the reverse behavior: down-regulation and
cytoplasmic or nuclear re-localization of E-cadherin and up-regulation of N-cadherin.
Collectively, these data demonstrate that SPARC-overexpression in tumor cells
promotes EMT (Fig.5). Finally, according to the increased tumor grade, lung
metastases were only found in BALB/c mice injected with SN25ASP or N3DSPARC
cells, but not with the wt counterpart. SPARC transduction into SN25A mammary cells
endowed them with the ability to metastasize to lung tissues. Indeed, the quantification
of digital images performed on multiple lung sections indicated that SN25ASP tumor-
bearing mice present a statistically significant increase in the frequency of lung
metastasis compared with SN25A tumor-bearing mice, (85% vs 15%, p-0.095) (Fig.6-
A) as well as in the number of lung metastasis lesions (9.5 vs 0.2, p-0.001) as shown in
Fig. 6-B. Accordingly, the increased number of metastatic areas/lung observed for
SN25ASP tumor-bearing mice was associated to increased metastatic tumor burden
(8500 11m2vs 200 11m2,p-0.0081), here presented as mean values (±SD) of
disseminated tumor cells areas measured by ImageJ software and expressed as
pixel/urn' units (Fig. 6-C). Collectively these data indicate that only upon SPARC-
transduction we can observe an overall massive substitution of lung tissues with tumor
cells. Interestingly, the injection of SN2SASP cells into the mammary fat pad of
syngeneic BALB/c mice, as showed in the representative section, resulted in the
formation of nested tumor cells that, disseminated in lung parenchyma, destroy the
lung typical structure, and are often associated with bone marrow-derived cells with
different myeloid morphology (Fig. 6-D).
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Fig.2 SPARe-transduction in SN25A cells promotes breast cancer aggressiveness.
(A) Tumorigenicity of SN25A and SN25ASP cell lines subcutaneously injected in BALB/c
mice. Results show the mean of tumor volumes ±SEM. One representative experiment out of
4 performed is shown. (B) SN25ASP murine breast tumor has features of human invasive
ductal carcinoma. Invasive human ductal breast cancer (upper panels) is characterized by
tumor cells infiltrating the dense stroma. Similarly murine SN25ASP tumors show cords of
tumor cells intermingled with the abundant stroma (lower panels).
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Fig.3 SN25ASP but not SN25A tumors have "mesenchymal" features in vivo.
H&E shows that SN25A tumors are well-differentiated adenocarcinomas with a lobular
structure in which nest of tumor cells are surrounded by a stromal septa (A) on the contrary
SN25ASP tumors are characterized by the absence of a lobular structure, in these tumors
lobular septa are interrupted and interposed with spindle-like shape tumor cells (B). In
SN25ASP (D) but not SN25A tumor (C) tumor cells (arrows) invade the surrounding stromal
margins (S, graph parenthesis). Mitosis are evident in SN25A (E) but not SN25ASP tumors
(F) that have a reduced proliferative capacity in vivo, according to the "mesenchymal"
phenotype.
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Fig.4 SPARe overexpression in N3D tumors does not affect tumor growth but promotes
EMT and collagen deposition.
(A) BALB/c female mice were subcutaneously injected with N3D or N3DSPARC cells.
Results are shown as mean of tumor growth ±SD. *P<0.05. (n=10) (B) Histological (H&E)
analysis shows the presence of spindle-shape tumor cells invading the surrounding stroma in
N3DSPARC tumors but not in N3D parental counterpart (arrows). (C) As in the SN25SP
tumors, also in N3DSPARC model we found cords of tumor cells intermingled with the
abundant stroma fibers (Gomori staining) In parental N3D tumors, the stroma was less
abundant and defining the lobular architecture. (D) The mesenchymal phenotype of
N3DSPARC tumor cells is confirmed, the high collagen production not restricted to the
stromal cells, as in the parental N3D tumors, but extending to the tumor cells (Masson's
trichrome staining).
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Fig.5 In vivo analysis of EMT markers in SN25A and SN25ASP tumors.
Expression of E-Cadherin and N-Cadherin in SN25A and SN25ASP tumors. Frozen sections
of SN25A and SN25ASP tumors obtained from BALB/c mice were stained with Abs to E-
cadherin (a-b) and N-cadherin (c-d). The picture shows the high expression of E-cadherin in
SN25A tumor but not in the SN25ASP counterpart in which tumor cells gain the expression
of N-cadherin. In SN25A tumors E-cadherin shows a cell membrane localization that is
functional for the epithelial phenotype. On the contrary in SN25ASP tumor were E-cadherin
is almost lost, N-cadherin shows a nuclear pattern, that is functional for EMT (original
magnification xl 00) (a-b); (original magnificationx200) (c-d).
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Fig. 6 Tumor-derived SPARe promotes tumor aggressiveness and lung metastasis.
SN25A and SN25ASP cell lines were injected in BALB/c mice s.c. and metastases were
checked 40 days after tumor injection (A) Quantification of lung metastasis frequency (mice
with lung metastases per total mice %) after SN25A and SN25ASP cell lines injection in
BALB/c mice. Results are reported as mean values (±SO) expressed as percentage n=IO
(Student's Hest p=0.095) (B) Metastatic lesions for lung surface were counted in the group
described in (A). The graph shows the average number of metastases (±SO) in each group. The
number of metastatic lesions was counted considering a total number of 10 areas for lung
(Student's t-test p=O.OOI). (C) Digital quantification of lung metastasis burden obtained by
objective morphometric analysis using ImageJ. The values reported in the graph represent the
mean area occupied by tumor indicated as IJ.m2• The analysis included a group of n=IO mice;
error bars indicated SO (Student's t-test p=O.0081). (D) Representative image of lungs tissues
isolated from SN25A and SN25ASP tumor bearing mice. Lungs from SN25ASP but not
SN25A tumors show an overall increased cellularity depending from the presence of tumor
cells invading the normal parenchyma structure (a-b). Notably the presence of lung metastases
in SN25ASP tumor-bearing mice correlated with the enrichment in pro-tumoral (circular
nuclei, black arrows) myeloid cells infiltration (original magnification x200). By contrast,
lungs from SN25A tumor-bearing mice showed the presence of anti-tumor (hypersegmented
nuclei, red arrows) myeloid cells (a-c). This data represents the first observation of SPARC-
expression in tumor cells skewing the myeloid cells phenotype.
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4.1.3 EMT determines Doxil (Pegylated Doxorubicin) resistance
To evaluate the impact of SPARC-driven EMT on drug resistance, BALB/c
mice were injected with SN25A and SN25ASP cells and treated with Doxorubicin (10
mg/kg, i.v.) starting 15 days after tumor cells injection, when tumors reached 10 mm",
The treatment was maintained according to the schedule shown in Fig. 7-A. Tumor
sizes were measured twice a week and mice sacrificed at day 40. The treatment
efficacy was calculated as percentage of tumor volume reduction at the end point of the
experiment. We found that the overexpression of SPARe in SN25A cell lines
significantly reduced the sensitivity to Doxil (60% vs 90% of tumor reduction rate)
compared with the wt counterpart (Fig. 7-B). Interestingly, the in vivo resistance of
SN25ASP cells was not reflected in their in vitro sensitivity since SN25ASP and
SN25A cells showed the same reduction in proliferation upon Doxil treatment (Fig. 7-
C) in vitro. These data were in line with the finding that SN25ASP cells did not
undergo EMT in vitro, but showed a similar expression of epithelial and mesenchymal
markers such as Ep-CAM (G88), E-cadherin (E-CAD), B-catenin, neural cell adhesion
molecule (N-CAM), Vimentin and integrin B1 (CD29) as assessed by
immune fluorescence (Fig.8-A) or flow cytometry (Fig.8-B). The only significant
difference was related to the increased expression of CD29 in SN25ASP compared to
SN25A in agreement with published data showing SPARC directly associated with
CD29 )39, 140(Fig. 8-B). Collectively, these data suggest that the EMT -driven by
SPARC is not cell-intrinsic, occurs in vivo and not in vitro, and is therefore likely to
need the support of host cells either from the immune system or the mesenchymal
reservoire.
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Fig. 7 SPARe overexpression increases in vivo Doxil resistance.
(A) SN25A and SN25ASP cell lines were injected in BALB/c and tumors were treated twice,
on days 15 and 30, with 10 mg/kg of Doxil according to the schedule reported. (B) The
efficacy of Doxorubicin treatment on SN25A and SN25ASP tumors was calculated at day 40
and showed as % of tumor volume reduction (Mean tumor volume (MTV) untreated-MTV
treated/MTV Untreated* 100) ***p<O.OOl n=20. Data represent a pull of 4 independent
experiments each one of n=5 /group. (C) In vitro Doxil cytostatic effect. Cells were treated
with Doxil for 24 h, 48 h, and 72 h. Proliferation was evaluated with MMT assay as ratio of
OD values referred to untreated cells.
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Fig. 8 Tumor-derived SPARe is not sufficient to induce EMT in vitro.
(A) Immunofluorescence analysis of B-catenin and Ep-CAM expression by SN25A and
SN25ASP cells, SN25A and SN25ASP cells were seeded onto poly-lysine coated glasses for
24h at 70% of confluence, fixed and stained with mAb to b-catenin and Ep-CAM. Both cell
lines express both markers on the cell membrane as typical for epithelial cells. (B) Expression
of Ep-CAM, N-CAM and CD29 by SN25A and SN25ASP, N3D, N3DSPARC, N2C cells in
vitro. FACS analysis shows tumor-derived SPARC do not influences Ep-CAM and N-CAM
regulation in SPARCNeuT derived mammary cell lines The only difference observed is the
increased CD29 expression by the SN25ASP in comparison to SN25A.
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4.1.4 SN25ASP tumors do not undergo EMT in vivo if injected into Spare" mice.
The concept of a non cell-autonomous and immune-dependent EMT is recent
and relatively new. Santisteban and colleagues'Y described the generation of breast
cancer stem cells through EMT as dependent on a functional immune system and
suggested that EMT may be a potential mechanism of immunoediting. In this line, the
skewing of immune cells within the tumor microenvironment from
immunosuppressive or tolerogenic, a feature that in terms of cytokines was reported as
Th2 or M2, to tumor tumor-eradicating (Th1 or M1 as cytokine profile) may have the
potential to reduce tumor invasion and metastasis by affecting EMT. We have
previously shown that in Spare" mice, Thl/Ml immune responsesl18 are more
pronounced. In addition, in a model of bleomycin-induced pulmonary fibrosis, we have
also found that in the absence of BM-derived SPARC, inflammation increases and
pulmonary fibrosis is exacerbated 121. These data suggest that SPARC may be involved
in the regulation of immune cells function. A further hypothesis is that such SPARC-
regulation on immune cells might occur through TGFB, whose signaling pathway may
lead to EMT. In our preliminary experiments, BM-derived macrophages from Spare +1+
and Spare" mice were treated or not with recombinant TGFB to test the down-
modulation of TNF- a expression, a mechanism that is implicated in the resolution of
inflammation. We found that Spare +1+ but not Spare" were able to down-modulate
TNF- a after TGF-B stimuli (Fig.9-A). Interestingly, Spare" macrophages were not
affected for TGF-B production (Fig. 9-B) that was even greater than in Sparci"
macrophages. This feature is shared by other cell types, i.e. fibroblasts and MSC, in
which SPARC affects TGF-B signaling, but not its production 114. The tight link
between SPARC and the immune system suggests its possible involvement in immune-
driven EMT in vivo. In other words, if our EMT phenotype was immune-mediated, the
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injection of SN25ASP tumor cells in Spare" mice whose immune system is per se
skewed towards a Th1M1 phenotype could prove our hypothesis. Thus SN25A and
SN25ASP cell lines have been injected in Spare" mice. H&E staining of those tumors
showed that SN25ASP tumors no longer displayed EMT features and did not invade
the surrounding tissues compared with as they did in Spare +/+ mice (Fig. lOA-D). IHC
analysis also showed that in SN25ASP tumors from Spare" mice, E-cadherin was
mainly expressed in the cell membrane, while it was preferentially expressed in the
cytoplasm in tumors from Spare +/+ mice. In agreement with the retention of an
epithelial phenotype, the SN25ASP tumors injected into Spare" mice were more
sensitive to Doxil growth-inhibition compared with the SN25ASP injected into
Spare +/+ mice (Fig. 11). By contrast, parental SN25A was equally sensitive to Doxil
treatment in both strains. These data suggest that EMT in vivo in SN25ASP tumors is
likely to be promoted by an immunosuppressive (Th21M2) phenotype molded by pro-
tumor myeloid cells.
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Fig. 9 TNF and TGF61 are reciprocally regulated in macrophages.
(A) TGF-13 inhibition of TNF- production by BM-derived macrophages. BM-macrophages
were seeded into a 96-well plate and treated with TGF-I3-1 (10 ng/ml) for 6 and 24h and
evaluated for TNF production by ELISA: TGF-131 inhibited TNF production by Spare but
not Spare- - macrophages. (B) TGF-131 production is not defective in Spare" macrophages.
WB analysis of TGFb 1 production by Spare + t and Spare-I- shows that Spare" macrophages
are competent for synthesizing TGF-I3-1 basally and upon TNF stimulation. BM-derived
macrophages from Spare' 'f and Spare" mice were seeded into 6-well culture plate in lMDM
2% FCS in the presence of recombinant murine TNF (10 ng/ml) for 16h. Cells were then
harvested and analysed for TGF-13 production by Western Blot by using a specific purified rat
anti-mouse TGF-13.
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Fig. 10 Histological analysis of SN25ASP tumors from Sparc'" and Sparc-l- mice.
(A) H&E shows that SN25ASP tumors from Spare- - contrary to that from Spare mice (a-
b), lost any EMT feature with tumor cells rounded (c) and not invading (arrows) the
surrounding stromal (d) margins (S, graph parenthesis); (B) E-cadherin expression in
SN25ASP tumors from Spare" mice is mostly on the cell membrane, while cytoplasmic In
tumors from Spare I mice.
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Fig.ll Effect of Doxorubicin treatment on SN25A and SN25ASP growth in Spare" mice.
Doxorubicin efficacy in Spare" mice was calculated as % of tumor reduction at 40 day. A
pull of 4 independent experiments (n=5, each experiment) is shown.
4.1.5 TM-derived SPARe promotes EMT by regulating tumor infiltration by myeloid
cells
Myeloid cells have long been know to be involved in tumor growth and
metastasis and recently their possible involvement in EMT was also hypothesised 78,
Spare +/+ Spare-/-
142. We evaluated myeloid cells recruitment in SN25A and SN25ASP tumors grown in
Spare+1+ and Spare" mice. In Spare +1+ mice, we found a higher number of myeloid
cells (GR-l +) infiltrating SN25ASP tumors compared with the non transduced SN25A
tumors. (Fig. 12 A-B) When both cell lines were injected in Spare" mice, we found no
difference in the number of infiltrating myeloid cells in the tumors, in agreement with
the hypothesis that the absence of host-derived SPARC activates the immune system
(Fig.12 C-D) also by promoting myeloid cells recruitment 138. Thus, if the hypothesis
of the immune-mediated EMT is true, myeloid cells recruited in Spare +1+ mice by
SN25ASP tumors should be functionally different from those recruited in the total
absence of SPARC. In fact, an interesting corroborating evidence emerged from the
analysis of tumors from Spare" mice: in these tumors the distribution of Gr-I cell
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seemed to attack tumors creating area of necrosis and vascular lacunae (Fig. 12-E). We
have previously demonstrated that GR-}+ neutrophils isolated from agar plugs injected
into the dorsal skin of micel43 are able to inhibits tumor cells proliferation. Thus, we
performed an in vitro proliferation assay in which SN25A and SN25ASP cells were
co-cultured for 24h with different doses of PMN from Spare +1+ and Spare" mice. We
found that SN25A was more sensitive to the citostatic effect of Spare +1+ PMN as, even
at the lower PMN-tumor cells ratio, the inhibition of tumor proliferation was nearly
70% in SN25A while it was 10-20% in SN25ASP, indicating that, as for our
hypothesis, this cell line is capable to re-direct PMN to a more tumor supportive
phenotype (Fig. 13-A). Interestingly, this effect was partially inhibited in the presence
of Sparc-I- PMN (30-50% growth inhibition) suggesting that in absence of SPARC,
PMNs increase their capability to kill tumor cells (Fig. 13-B). In the Spare" host. the
reduced ECM deposition favors myeloid cells infiltration, as we have previously
demonstrated. However, in the Spare" host, myeloid cells are more activated and
capable of attacking tumor cells, explaining why in both SN25A and SN25ASP
tumors, we have areas of necrosis related to PMN recruitment. Moreover, in tumor
from Spare" mice, IL}0 is reduced and a less suppressive environment is expected.
Another way to test whether Spare" GR-} cells are more prone to becoming effector
rather then protumoral cells, was to isolate notably immunosuppressive myeloid cells
(MOSCs) from tumor bearing SPARC-NeuI and BALB-NeuT mice'", to inject them
into SN25ASP bearing mice and evaluate the effect on tumor growth (Fig. 14). We
found that MOSCs from Spare +1+ tumor-bearing mice significantly increased the
growth of SN25ASP tumors compared with mice that did not receive MOSCs i.v. By
contrast, MDSCs from Spare" tumor-bearing mice, despite their increased production
of VEGF, a factor that was involved in their tumor-promoting activity, were less
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efficient in sustaining tumor growth. Finally to demonstrate that defective-myeloid
cells in Spare-I- mice are responsible for the reversion of the EMT phenotype we
performed an experiment in which tumor-bearing Spare" mice were adoptively
transferred with myeloid cells from wt mice and tumors evaluated for EMT features. In
detail Spare" mice were injected with SN25ASP cells and transferred with 1.106
myeloid cells once a week considering a size of 8 mrrr' the starting point for myeloid
cell transfer. We found that myeloid cells from wt, but not from Spare" mice were
able to promote EMT in SN25ASP tumors injected into Spare" mice (Fig.15). Taken
together, these data suggest that chemotherapy resistance may be related to the
acquisition of an EMT phenotype and that the interaction with the immune system is
very relevant to the acquisition of such phenotype. Within these cross-
communications, SPARC might be relevant in two ways:
1. SPARC produced by tumor cells is required for EMT. In line with this,
SPARC-negative tumor cells do not undergo EMT in vivo in Spare +1+ mice;
2. SPARe produced by host cells sustains EMT in vivo, by affecting myeloid
cells functionality.
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Fig.12 Myeloid cells recruitment in SN25A and SN25ASP tumors from Sparc'" and
Spare" mice. Myeloid cells were stained with a mAb to GR-t. In Spare mice a major
number of myeloid cells were recruited into SN25ASP tumors (A) in comparison to the
parental ones (B). In Spare- -mice a large number of myeloid cells infiltrated both SN25A (C)
and SN25ASP (D) tumors. (E). GR-I + cells attack tumor cells into SN25A tumors from
Spare- - mice such to create area of necrosis and vascular lacunae as showed by a staining of
GR-! cells (brown) with CD31 (red) that identifies vascular structures.
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Fig. 13 In vitro proliferation assay of SN25A and SN25ASP cell lines co-cultured with
Sparc'" and Spare" PMN. The capability of PMN from Spare' mice to inhibit tumor
proliferation is reduced in SN25ASP in comparison to the parental cell line (A-B white-grey
bars). This effect is partially reverted in the presence of PMN from Spare" mice (B).
96
A B
3200
2800
2400
2000
N~1600
1200
800
400
O+-----~~~~----.-----~
o
--e- No transfer
___ MDSC from Spare.l+
___ MDSC from Spare·l·
3500
10 20
Days
30 40
c
2000
... 1
Clw
:: 1
i
Fig. 14 Effect of myeloid cells injection on SN25ASP tumor growth.
SN25ASP tumor-bearing mice (8 mrrr') were injected i.v. with 2,5 * I06 MOSC isolated from
the spleen of tumor bearing SPARe-NeuT and BALB-NeuT mice. MOSes from Spare but
not Spare" increased the growth of SN25ASP tumor in comparison to untreated mice (A-B)
although MOSes from Spare" mice were most effecting in mobilizing VEGF in the serum
(ELISA assay) (C), a factor that has been implicated in mammary tumors growth.
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Fig.15 MDSCs from Sparc'" mice induces EMT in vivo.
Spare- - mice were injected with SN25ASP cells and adoptively transferred with MD s
isolated from tumor-bearing Spare- - and Spare + I donors. Forty-days later recipient m ice were
sacrificed and tumor histologically evaluated for EMT. We found that myeloid cells from
Spare +, but not from Spare- -mice were able to promote EMT in SN25ASP tumors injected
into Spare -mice as H&E staining showed an increased tumor grade, the presence of spindle-
shape cells, the loose of tumor septa and margins.
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4.1.6 Tumor-derived SPARe affects myeloid-derived suppressor cells and contribute
to tumor immunosuppression
The injection of transplantable murine breast carcinoma cells in mice has been
associated with marked leukemic reaction 144, 145, 146, 147 characterized by the
accumulation of neutrophils within the blood or with the expansion of immature
myeloid cells including MDSC, in primary and secondary lymphoid organs 49. In this
context the spleen is now considered a crucial organ for tumor-induced tolerance as it
is the main lymphoid organ that undergoes myeloid-derived suppressor cells (MDSC)
expansion during tumor development in mice. This suggests that the functional
characterization of myeloid cells could be performed in the spleen, where the
purification of these cells is easier than in tumors. Beside being associated with
immunosuppressive activities, MDSC are also involved in promoting EMT, prompting
the idea that a different myeloid cells expansion or activation might be induced by the
injection of SN25A or SN25ASP tumors in mice. The fine discrimination of MDSC
could be exerted, by FACS, by using a mAb to Ly6C combined with a mAb to Ly6G.
In particular, within the gate of COlI b+ cells, monocytic MDSCs (M-MDSC) are
defined as Ly6G lowlLy6Chighwhereas granulocytic MDSCs (G-MDSC) are Ly6G
highILy6Clow148. Under this premises, I analyzed peripheral blood, spleen and BM of
mice bearing SN25A versus SN25ASP tumors. I found that both cell lines determined
an expansion of myeloid cells and of their precursors in the spleen and bone marrow
(Fig.l6). The only minor difference I observed among the two cell lines was in the
peripheral blood, where I found a higher percentage of M-MDSC in SN25ASP tumor-
bearing mice (Fig. 17). As these differences were too small to explain the different
phenotypes of SN25A and SN25ASP tumors in vivo, we considered the possibility that
tumor-derived SPARC might affect the modulation of the phenotype of myeloid cells,
99
rather than just promoting their expansion. The phenotype of myeloid cells could be
evinced by gene expression or through a functional assay based on the capability of
MOSC to suppress the proliferation of C04 and C08 T cells. In the first case the
evaluation of myeloid cells phenotype through gene expression was based on some
genes that mark MOSCs and overlap for expression those distinguishing N2 and N 1-
polarized neutrophils 149,150. Indeed MOSC and N2-neutrophils express Arginase-I,
CCL2, CCL5, VEGF, MMP9 and STAT3 whereas Nl-neutrophils express CCL3 but
are low for CCL2, CCL5, Arginase and STAT3. I have purified M-MOSC and G-
MOSC from the tumor and the spleen of SN25A and SN25ASP-tumor bearing mice by
magnetic beads separation, and performed a quantitative PCR analysis to check the
differential expression of the above listed chemokines. I found that M-MOSC isolated
from the spleen of SN25ASP tumor-bearing mice express significantly higher levels of
CCL2, CCL5, and STAT3 compared with M-MOSC isolated from the spleen of
SN25A-bearers (Fig. 18-A). Confirmatory results were obtained from MOSC isolated
from the tumor, where I found that CCL2 gene was more highly expressed by M-
MOSC isolated from SN25ASP rather than from SN25A tumors (20 vs 40 fold change
expression) (Fig. 18-B). Accordingly I have compared the ability of spleen-purified
MOSC from SN25A and SN25ASP-tumor-bearing mice to suppress a-C03 and a-
C028 induced T cells proliferation. I found that MOSCs spleen-purified from
SN25ASP tumor bearing mice have a higher capacity to suppress T cells proliferation
(Fig. 19-A-B).
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These data indicates that M-MOSC induced by SN25ASP are more suppressive than
those induced by SN25A tumors. Thus, tumor-derived SPARC modulates the
phenotype of tumor-induced MOSCs toward immunosuppression. In agreement, in
vivo analysis of cytokine production showed an increased production of IL-l 0 the most
potent immunosuppressive cytokine in the microenvironment of SN25ASP tumors
compared with the wt counterpart (Fig. 19-C).
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Fig.16 Analysis of myeloid cells precursors populations in BM and SPL of BALB/c
injected with SN25A and SN25ASP cell lines.
FACS analysis for myeloid cells precursors was performed in BM and spleen, of BALB/c
mice injected with SN25A and SN25ASP cell lines. Lin-cKit+ (LK), common myeloid
progenitor (CMP), granulocyte-macrophage progenitor (GM P), megakaryocytic/erythroid
progenitor (MEP), have been determined by staining BM or spleen cells with antibodies for
lineage (Lin) positive cells including CD3, CD 11b, CD45R, Ly-6G, CD4, CD8, Ter-119, for
stem cell and progenitors including CD11?, CD34, and CDI6/CD32. (A) Representative plots
showing the gating strategy that has been used: LK are gated first and, within the LK gate, the
three GMP, CMP and MEP populations are identified according to the different expression of
CD34 and CD16/32 (B-C). Percentage of LK cells in BM and spleen cell suspension showing
an increased frequency of LK+ cells in the spleen of tumor bearing mice injected with
SN25A and SN25ASP tumors in comparison to tumor-free mice. This difference was not
found in the BM according to the spleen as major organ buffering myeloid cells expansion in
mice. (D-E) Fraction of GMP, CMP, MEP precursors in BM and spleen showing that
SN25ASP tumor-bearing mice have an increased frequency of MEP (p<O.05) whereas
SN25A tumor bearing mice presented a slightly increased in GMP precursors (p<O.05
significance).
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Fig.17 Analysis of MDSC subsets in PBMC of BALB/c injected with SN25A and
SN25ASP cell lines.
CA) Representative plot showing the gating strategy used to identify the different myeloid
cells subsets. Granulocytic-MDSC and Monocytic-MOSC are identified within the gate of
COIl b+ cell based on the expression of Ly6G and Ly6C markers. Granulocytic-MOSC are
Ly6Ghi Ly6C'OWcells whereas Monocytic-MOSC are Ly6G'oWLy6Chi cells. CB) Frequency of
granulocytic and monocytic MDSC in the PBMC of SN2SA and SN2SASP tumor-bearing
mice showing the increased frequency of monocytic MDSC in the spleen of SN2SSP tumor-
bearing mice (p< 0.05; Student t test).
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Fig.18 Characterization of MDSC phenotype in SN25A and SN25ASP tumors.
(A) Quantitative real time-PCR analysis for protumoral, el2 and cl5, or
immunosuppressive markers, Argl and Stat3, was performed on myeloid cells (Ly6 hi
Ly6CIOWand Ly6Ghi Ly6CIOW subsets) isolated from the spleen of SN25A and SN25 P tum r-
bearing mice. The picture shows data from a pool of RNA extracted from n=IO/gr up mic.
Data are representative of 3 independent experiments. The fold change in expression of the
target genes relative to the internal control gene (GAPDH) is shown. The mean fold change in
expression of the target gene is calculated as 2-·,CT where 6.1::J. T= ( ,arget-
CT,GAPDH)sample- (CT,Target-C,GAPDH)internal control. CB) The same analysi was
performed on Ly6Ghi Ly6C1ow and Ly6Ghi Ly6C1ow myeloid cells subsets isolated from the
tumor of SN25A and SN25SP tumor-bearing mice. Data are indicative of 2 independent
experiments. Overall the analysis shows a significantly increased expression pro-tumoral and
immunosuppressive markers in myeloid cells isolated from SN25ASP tumor-bearing mice.
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Fig. 19 Tumor-derived SPARC influences MDSC immune suppressive activity.
Myeloid derived suppressor cells were purified using CD II b-conjiugated microbeads and
Myeloid-Derived Suppressor Cell Isolation Kit. 4 x 105 naive BALB/c splenocytes have been
labeled with CFSE and co-cultured with the different MDSC population at different ratio in
presence of 2 mg/rnl of soluble anti-CD3 and I mg/ml of anti-C028 to activate lymphocyte.
Each sample is seeded in triplicate. Proliferation of C04 and C08 T cells has be n a e ed 2
and 3 days later, by and evaluating CFSE dilution in the C04+ and C08+ gated populations.
Results are shown as percentage of proliferated cell. (A-B). Immune suppre sive activity of
the two subsets of MOSC from the spleen of SN25A and SN25ASP tumor bearing mice on
CD4 and C08 T cell proliferation in vitro; samples in triplicates. Experiment performed 3
times with overlapping results. CC) Immunohistochemistry for IL-I 0 performed on N25A or
SN25ASP frozen sections showing that SN25ASP tumor cells strongly express IL-I O.
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4.2 SPARC REGULATION OF MDSC FUNCTIONS:
POSSIBLE MECHANISMS
4.2.1 Tumor-derived SPARe shifts tile halance between GM-CSF and G-CSF re-
directing the tumor microenvironment
Having demonstrated that SPARC modulates the phenotype of myeloid cells
we then investigated mechanisms underlying such a regulation. GMCSF and GCSF,
are two main important hematopoietic cytokines expressed at different level in various
tumor subtype, which act as modulators of tumor growth 151. Most importantly these
two cytokines were involved in myeloid cells polarization: GM-CSF has been
implicated with the differentiation of pro-tumoral MDSC 152, whereas G-CSF was
linked to the production of anti-tumoral myeloid cells (N l-neutrophils) lS3. I quantified
GMCSF and GCSF production in the supernatants of SN25A and SN25ASP tumor cell
lines. To this end tumor cells were seeded onto a 6-well plate at a density of 1·106/ml;
supernatants were collected after 48 h for ELISA. I found a higher amount of GM-CSF
in the supernatants of SN25ASP tumor cell lines compared with the wt counterpart. By
contrast, supernatants from the same cell lines showed a decreased amount of G-CSF
(Fig. 20-A-B). These results indicated that SPARC transduction in SN25A cells shifted
the synthesis ofG-CSF towards GM-CSF. According to these in vitro data, the amount
of G-CSF in the sera was higher in SN25A tumor-bearing mice, whereas GM-CSF was
undetectable in sera from all groups (Fig. 20-B). Collectively these data suggest that
the unbalanced production of GMCSF on GCSF within the tumor microenvironment
might be responsible for the different re-direction of myeloid cells toward an
immunosuppressive phenotype in SN25ASP tumor-bearing mice. These data were in
line with the proliferation assay (Section 4.1.5; Fig. 13), in which we showed that
SN25A and SN25SP tumor cells were differently sensitive to the cytostatic effect of
106
PMN. In particular, SN25A (high G-CSF) was more sensitive to the cytostatic effect of
PMN; in fact, at lower doses of PMN (50:1, 25:1 and 12:1 ratio), the inhibition of
tumor proliferation was nearly 70%, whereas the same dose of PMN resulted in a 10-
20% inhibition in the SN25ASP cell line (producing higher GM-CSF) indicating that
as for our hypothesis, this cell line is capable to re-direct PMN toward a more
immunosuppressive phenotype (Fig. 13).
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Fig. 20 SPARC shifts the balance between GMCSF and GCSF production.
(A) GMCSF production by SN25A versus SN25ASP cell line was measured through LI A
assay performed on supernatant collected 48 h after cell seeding; "p < 0.05, ***p < 0.00 I
(n=2). (B) GCSF level in supernatants of SN25A and SN25ASP cell lines and in PB
(peripheral blood) of SN25A and SN25ASP BALB/c tumor bearing mice. Two independ I1t
experiments are shown.
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4.2.2 SPARe blocks the differentiation and maturation of myeloid cells
The immunosuppressive phenotype of MDSC is linked with the maintenance of
their "immature" state. The maintenance of this phenotype within the tumor is granted
by various growth factors including TGF_(3154.Our group has contributed to
demonstrating that SPARC regulates TGF-(3 signaling in immune cells, particularly
macrophages. We reasoned that the modulatory effect that we found on myeloid cells
could be in part related to the ability of SPARC to modulate TGF-f3 signaling, a
function dependent on cell-to-cell contact that might act on a microenvironment
differently rich in GM-CSF or G-CSF. To test this hypothesis, we performed in vitro
differentiation experiments in which tumor cells were co-cultured with hematopoietic
stem cells Lin- cells isolated from a normal BM, and left to differentiate over 7 days.
As an alternative approach, Lin- cells were cultured in the presence of 30% of
conditioned medium from SN25A or SN25ASP tumor cell and at day 7 analyzed at
FACS with mAbs to Ly6G-FITC conjugated, Ly6C-APC conjugated and CDllbPE-
conjugated. The results showed that when Lin- cells were seeded in contact with
SN25ASP tumors, their differentiation, evaluated as gain of COlI b, Ly6C, and Ly6G
markers, was inhibited, a response that was mimicked by treating Lin- cells with
recombinant TGF-f3. By contrast, supernatants from SN25A and SN25ASP tumors
were similarly capable of promoting Lin- cells differentiation in different subtypes of
myeloid cells without notable differences (Fig. 21). The same result was obtained by
seeding Lin- cells onto SN25A and SN25ASP tumors monolayer in the presence of a
transwell that abrogated the contact between tumor cells and Lin- cells. The results
indicated that SPARe modulates the phenotype of myeloid cells by both molding the
cytokines microenvironment and by a cell-to-cell contact-mediated effect. probably
TGF-B -dependent.
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Fig.21 Effect of SPARe-tumor derived on hematopoietic stem cells (LK)
differentiation.
Lin- cells were isolated from the BM by negative selection using a Lineage ell Depletion
Kit (Miltenyi). For co-culture experiments, 104 Lin-cells were seeded into a 24-well plate in
contact or not with a monolayer of SN25A or SN25ASP cells. Alternatively Lin- cells were
cultured in presence of 30% of conditioned medium from SN25A or SN25A P tumor cell.
Lin- cells differentiation was evaluated 7 days later at FACS with mAb to Ly6G-FI
conjugated, Ly6C-APC conjugated and CDII bPE-conjugated. The results showed that when
Lin- cells were seeded in contact with SN25ASP tumors their differentiation, the gain of
CDII b, Ly6C, and Ly6G markers was inhibited, a condition that was mimicked by the
treatment of Lin- cells with recombinant TGF-f3. On the contrary supernatants from N25A
and SN25ASP tumors were similarly capable to promote Lin- cells differentiation in the
different myeloid cells subtypes without any differences. Data are representative of two
experiments.
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4.2.3 Cox-2 involvement in SPARC-regulation of MDSCfunctions
Prompted by the above results, we tried to understand how SPARC modulates
the GM-CSF and G-CSF production. I thought that a possible mechanism through
which SPARC might regulate myeloid cells phenotype is by its ability to regulate
ECM deposition. Accordingly, ECM directly influences the expression of the
cyclooxygenase II (COX-2), an enzyme that is regulated during myelopoiesis and that
has been shown to shift the balance between G-SCF and GM-CSF in favor of GM-CSF
in human mesangial cells 100. I therefore evaluated the expression of collagen and
COX-2 in SN25ASP vs SN25A tumors. Being mesenchymal cells, SN25ASP cells in
vivo express higher levels of collagens compared with SN25A cells (Fig. 22).
Moreover, I found that SN25ASP tumor showed a higher COX-2 expression,
especially in infiltrating immune cells (Fig.23-A). Quantitative qPCR analysis
performed on MDSC isolated from SN25A and SN25ASP tumors showed that
monocytic MDSC from SN25ASP but not SN25A tumors express COX-2 together
with NOS2 and Arginase I (Fig.23-B). This enzyme plays a key role in tumor
progression also by affecting immune cells for example by blocking M2 Macrophage
Differentiation ISS, we therefore hypothesized that it could also be involved in MDSC
functions, such as promoting EMT.
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Fig.22 Masson's trichrome stain of SN25A and SN25ASP tumors.
SN25ASP shows an overall increased collagen deposition in comparison to the wt
counterpart. a-b) (original magnification xl 00); c-d) ( original magnification x200).
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Fig.23 SPARC transduction regulates COX-2 expression in SN25A tumors.
CA) Immunohistochemistry analysis for Cox-2 expression was performed on SN25A and
SN25ASP frozen sections. The poorly differentiated SN2ASP tumor expressed COX-2 both
in tumor cells and within the myelo-monocytic infiltrate. (b-d). On the contrary N25A
tumors were negative for Cox-2 expression or slightly positivity in stromal cells (a-c). (a-b)
(original magnification x100) ; (c-d) (original magnification x200) . (B) Quantitative qPCR
analysis for Cox-2, Nos-2, ArgJ genes was performed on Ly6GhighLy6Clow and Ly6G1ow
Ly6Chigh myeloid cells subsets isolated from the tumor of SN25A and SN25SP tumor-bearing
mice. Data are indicative of 2 independent experiments. The analysis shows a significative
upregulation in Cox-2 gene expression in Ly6G1ow Ly6Chigh cells isolated from NA25 P
tumors. Cox-2 upregulation in these cells was associated with an increased expression of
Argl and Nos-2 genes. The analysis included a pooled RNA extracted from n=IO/group mice.
(*** p= 0,0159; *:::;0.05,Student t test.
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4.3 MYELOID
TARGETING AS
CHEMOTHERAPY
DERIVED SUPPRESSOR CELLS
STRATEGY TO IMPROVE
So far we have demonstrated that SPARC production by tumor cells promotes
tumor aggressiveness through a modulation of myeloid cells. We reasoned that if
myeloid cells are ultimately responsible for the EMT phenotype their specific targeting
should be able of revert the EMT phenotype and finally restore the sensitivity of
SN25ASP tumor cells to chemotherapy. To target myeloid cells we decided to use two
different strategies: amino-bisphosphonates and COX-2 inhibitors.
4.3.1 Aminobisphosphonates reduces aggressiveness of SN25ASP tumors in vivo
without significantly affecting MDSCs expansion
Aminobisphosphonates (NBPs) are drugs commonly used to treat bone disease
in solid cancer and multiple myeloma, and to prevent bone loss in osteoporosis.
Zoledronic acid (Zometa), the most potent NBP currently available for clinical use, is a
specific inhibitor of famesyl pyrophosphate synthase (FPPS) in the mevalonate (Mev)
pathway. The Mev pathway is a highly conserved metabolic cascade that converts Mev
into sterols, such as cholesterol, and nonsterol isoprenoids. such as famesyl
pyrophosphate and geranyIgeranyI pyrophosphate. Cholesterol is critical for the
physicochemical properties of all eukaryotic cells, whereas isoprenoids are required for
the isoprenylation and activation of small G-proteins, like Ras and Rho, that control
cell proliferation, cytoskeleton remodeling, motility and angiogenesis. The metabolic
consequences of Zometa-induced FPPS inhibition are two-fold: (1) a decreased content
of intracellular isoprenoids leading to dysfunctional G-proteins and alterations of their
downstream signaling pathways; and (2) an intracellular accumulation of isopentenyl
pyrophosphate (IPP) leading to the formation of l-adenosin-S'-yl ester 3-(3-methylbut-
3-enyl) ester triphosphoric acid. a pro-apoptotic ATP analog generated by combination
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of IPP with AMP by aminoacyl-tRNA-synthetase. In our laboratory, Melani et at. have
demonstrated that, by reducing MDses expansion, lometa treatment overcomes the
tumor-induced immune suppression and improves the generation and maintenance of
antitumor immune response induced by immunization against the pI85/HER-2. The
study, however, did not identify the pathway (i.e. Mev pathway) affected in Moses by
the lometa treatment", Reproducing the experiment by Melani et al 49 SN25ASP
tumor-bearing mice were daily treated with 0,1 mg/kg of Zoledronic acid (lometa)
(subcutaneously). Treated and untreated mice were checked once a week for MOSe
expansion in the peripheral blood and, at the end of the experiment, tumors were
harvested for histology and IHe (Fig. 24-25). In contrast with Melani et al, I found that
the treatment did not significantly affect tumor growth, as BALB/c mice injected with
SN25ASP and treated with lometa presented no significant changes in tumor volume
reduction at the end point of the experiment (Fig. 24). However, histological analysis
of SN25ASP tumors from lometa treated mice indicated a complete reversion of the
EMT phenotype in vivo (Fig. 25). IHe analysis for iNOS expression performed on
frozen tumor sections showed downregulation of iNOS production in myeloid cells
from lometa-treated tumors that was associated to an unchanged number of Ly6G+
cells in tumors (Fig. 26-A). Again, these results suggest the possibility that an altered
phenotype of myeloid cell, in this case associated with the lometa treatment, rather
than impairing recruitment, might be responsible for EMT reversion. Interestingly, the
PB (peripheral blood) of lometa treated mice showed an imbalance in the frequency of
CDllb+Ly6Ghigh Ly6e1ow and COllb+Ly6G1ow Ly6ehigh subset of myeloid cells in
favor of the COlI b+Ly6Ghigh population (Fig. 26-B). In agreement with the EMT
reversion, SN25ASP tumor-bearing mice treated with lometa, showed a reduction in
the frequency of lung metastasis (Fig. 27). Finally, SN25ASP tumor bearing mice
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treated with Zometa showed an increased infiltration of granulocytes III the lung
associated with a reduced number of infiltrating tumor cells.
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Fig. 24 Zoledronate don't affect significantly tumor growth of SN25ASP tumors.
BALB/c mice were subcutaneously injected with SN2SASP cells and treated with Zorn eta
(0,1 Jl g/mouse, s.c.). Treatment was started on day 15 and continued every day until
sacrifice. Results are presented as mean tumor volume ± SEM. *P<O.OS. Data are
representative of three independent experiments.
115
AFig. 25 Zometa reverts the mesenchymal phenotype of SN25ASP tumors.
(A) Histological (H&E) analysis of SN25ASP tumors treated with Zometa shows that the
drug changed the tumor morphology from a mesenchymal to a more epithelial phenotyp .
Scale bars 100 urn. (B) IHC analysis for E-cadherin and N-cadherin markers in SN2SA P
tumors treated or not with Zometa shows E-cadherin strongly re-expressed in SN2SA P
treated tumors. SN25ASP untreated tumors showed an increased N-cadherin expression;
Zometa treatment reduces N-cadherin expression in SN25ASP tumor.
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Fig.26 Zometa treatment affects the activity of MDSC but not their expansion.
(A) IHC analysis for Gr-l and iNOS performed on frozen section of SN25ASP tumors treated
or not with lometa.
SN25ASP untreated and lometa-treated tumorwere checked for myeloid cells infiltration and
immunosuppressive activity. Tumors sections were stained with Gr- 1 mAb for myeloid cells
and a polyclonal antibody against iNOS (Cayman) for ROS production (a-b); (c-d). lometa-
treated and untread tumors were equally infiltrated by Gr-l + myeloid cells (e-t); (c;d)
however Zometa-treated tumors showed a reduction in the number of infiltrating iNOS+
myeloid cells (c-d); (a-b). (B) FACS analysis for circulating myeloid cells performed on PB
from SN25ASP tumor-bearing mice treated or not with 0.1 mg/kg of Zometa. (p:SO.OS,
Student t test).
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Fig.27 Zometa treatment reduces lung metastasis and increases the number of
granulocytes in SN25ASP tumor bearing mice.
SN25ASP cell lines were injected in BALB/c mice and tumors treated or not with Zometa.
40-days later mice were sacrificed and lungs removed for histological analysis. H&E
performed on lung sections showed that Zometa treatment overall reduced the lung cellularity
that in untreated tumors was associated to the presence of infiltrating tumor cells.
Interestingly, Zorneta-treatrnent increased lung infiltration by anti-tumor granulocytes
(hypersegmented myeloid cells, arrows), a data that confirmed the ability of Zometa to elicit
anti-tumor activities of myeloid cells.
4.3.2 Zometa affects MDSC phenotype and/unction
G-MDSC and M-MDSC were magnetically sorted from the spleen of SN25A
and SNA25ASP tumor-bearing mice treated or not with Zometa. Quantitative real-time
PCR was performed to evaluate the expression of the MDSC pro-tumoral marker
(Section 4.1.6) CCL2, CCLS, NOS2 and STAT3. Overall, I observed a significant
downregulation of these markers particularly in the M-MDSC subset, where Zometa
treatment strongly reduced CCL2, CCLS and NOS2. In M-MDSC, moreover I found a
significant reduction in NOS2 and STAT3 (Fig. 28).
118
A Ccl2 Ccl5 Stat3
t ~1" LH'LLa_ nj , i
o
~~
B
Ccl2 Cel5
Untreated Zometa Untreated Zomela
Arg1 Nos-2
e
c .~ o Ly6G"' Ly6Ciow..
i .. _ LySG''''' LySC"'=;:-=~ ~~il tt.
E~
e~ 1. t.• ~:; ..
#. It
Untreated Zometa Untreated Zometa
Fig.28 Zometa treatment reduces pro-tumoral and immunosuppressive markers in
myeloid cells.
(A) Quantitative RT-PCR analysis for CCL2, CeLS, STAT-3 was performed on plenic
Ly6dOWLy6Chighand Ly6GhighLy_6CIOWmyeloid cells subsets isolated from SN2SASP tumor
bearing mice treated or not with Zorn eta. Data show that Zometa treatment significantly
reduces the expression of CCL2, CCLS and Stat3 on Ly6GloWLy6Chighmyeloid cells (student t
test*p ~O.OS). (B) Quantitative RT-PCR analysis for CCL2, eCLS and ArgJ was perform
on Ly6G10W Ly6Chigh and Ly6Chigh Ly_6CIOWmyeloid cells sorted from tumor of N25A P
tumor bearing mice treated or not with Zometa. Zometa promotes a significantly
downregulation of protumoral markers CCL2 (-4 fold-change), CCLS (-2 fold change). M-
MDSC isolated from ZA-treated tumors significantly downregulated also immunesupre sive
markers Arg-I and NOS2 (-18 fold change). This data show that monocytic myeloid cell CM-
MSDC) isolated from SN25ASP tumor bearing mice acquired an anti-tumor phenotype aft r
Zometa treatment. Data are indicative of 2 independent experiments.(*** p~O.OJ;** p= 0.02,
Student t test).
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4.3.3 Doxorubicin plus Zometa increases Doxil efficacy in SN25ASP-resistant
tumors
We reasoned that, if the resistance to Doxil treatment showed by SN25SP
tumor was related to their mesenchymal phenotype, a combination of Zoledronic acid
(Zometa) and Doxil could be efficient in overcoming this phenotype. Thus SN25ASP
tumor-bearing mice were treated with 10 mg/kg of Doxil i.v, once a week, and daily
s.c. with 0.1 mglkg of Zometa according to the reported schedule (Section 2.2.J). The
treatment was started when the tumor size was nearly 20 mm'. Tumor-bearing mice
were randomized and divided in 4 groups. The first group was treated with Doxil
alone, the second group with Zometa alone, the third received the combined treatment
while the last group remained untreated. I found that, in agreement with my
hypothesis, mice that had received the combined therapy showed an increased
sensitivity to Doxil treatment. Cumulative data are summarized in (Fig 29-A) and
reported as percentage of tumor reduction at end point (Fig.29-B). In summary, the
data suggest that the immunomodulatory effect induced by Zoledronic acid in myeloid
cells could improve chemotherapy response. Finally, I have evaluated the possibility
that Zometa-treatment, particularly in combination with Doxil, might also interfere
with the immunosuppressive activity of myeloid cells, so I tested whether myeloid
cells isolated from the spleen of Zometa+Doxil-treated SN25ASP tumor-bearing mice
had a reduced ability to suppress the proliferation of a-CD3/aCD28 stimulated
splenocytes. I found that MDSC isolated from Zometa+Doxil treated mice was
significantly less efficient in inhibiting the proliferation of CD8 T cells (Fig.30-A-D).
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Fig.29 Zometa treatment enhances Doxil efficacy on SN25ASP tumors.
SN25ASP tumor-bearing mice were daily injected with 0.1 mg/kg of Zoledronic acid
(lometa) and treated once a week with to mg/kg of Doxil. (A) Bars refers to cumulative data
show mean of tumor volume (mm3) relative to SN25ASP tumors injected in BALB/c mice
and treated with Doxil , lometa alone or combined drugs at the endpoint of the experiment.
Data are reported as (mean±SEM) n=25. (B). lometa alone reduced tumor volume (mm3
(~0.05) 50%; Doxil alone 60% (p~0.05); Doxil + Zometa 100% tumor reduction
(***p=0,0005). SN25ASP tumors treated with lometa are more responsive to 00 it (Z meta
vs Doxit+Zometa * p~0.05). Tumor reduction was calculated at endpoint of the experiment.
Statistical analysis were done using one-way ANOYA with Dun's multiple comparison Test.
121
A B
GATED on COBT cells
(in presence of Gr-1 cells)
GATED on CD4+ T cells
(in presence of Gr-1 cells)
100 CJDoxl1.. ,.. .- _Doxll +Zoledronate'8 75
go ..-
~ r-
~ 50e
... 25
'0 Inif. o In
/. ~~ />\. ~\. ,,<!,\. ~\.
'" ~;f'
~"","
100
c::JDoxii
_ Doxll + Zoiedronate
.!!..
u 75
~
~ 50~
I 25
'0
if.
O-'Lrl ..... .L.,.L
~"# ,,"" ,f'"," .,#'
~"","
Fig.30 MSDC from Zometa-treated mice had a decreased capability to suppress T cells
proliferation.
Immune suppressive actrvity of the two subsets of MDSC isolated from the spleen of
SN25ASP tumor bearing mice, treated or not with Zometa, on CD4 and CD8 T cell
proliferation in vitro; samples in triplicates. Experiment performed 3 times with overlapping
results (A-B).
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4.3.4 COX-2 inhibitors affects MDSC recruitment and ameliorate the sensitivity to
Doxil treatment.
The use of COX-2 inhibitors in our models stemmed from my original finding
that SPARC transduction in tumor cells promotes COX-2 expression by infiltrating
myeloid cell. Consequently, I reasoned that if COX-2 is functional for MOSC, it could
be a possible target to affect these cells and perhaps EMT. I tested the involvement of
COX-2 directly in vivo by treating SN25ASP tumor- bearing mice with a specific
COX-2 inhibitor (Celebrex), intradermally at a dose of 5 mg/kg as reported 59. The
read-out was tumor growth, MOSCs recruitment and EMT. I found that Celebrex
strongly affected tumor growth (Fig. 31-A) and inhibited MOSC accumulation (Fig.
31-B). Flow cytometry analysis performed 10 days after the start of treatment of
PBMC revealed that Celebrex significantly reduced the level of MOSC (Fig. 31-8). In
keeping with my hypothesis, histological analysis of tumor showed that the COX-2
inhibitors were able to revert the mesenchymal phenotype of SN25ASP tumors (Fig.
32-A). Following a procedure similar to that used for NBTs, Celebrex was used in
combination with Doxil. Again, I found that the combined therapy decidedly improved
the response to Doxil treatment (Fig. 32-B). Taken together, these data suggest that the
response to therapy of mesenchymal tumors might be enhanced by the association of
conventional therapeutics with immunomodulatory drugs like aminobisphosphonates
and COX-2 inhibitors.
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Fig.31 Celebrex treatment reduces tumor growth and PBMC MDSC in SN25A P
tumors.
(A) Tumor growth of SN25ASP untreated and SN25ASP Zometa treated tumors. Data are
shown as tumor volume mean ±SEM n=5 volume at 40 day CB) Reduction in the frequency of
Ly6Chi Ly6G10W (M-MDSC) and Ly6GhiLy6Clow (G-MDSC in the PB of SN25A P tumor-
bearuing mice treated with Celebrex (student t test; * p< 0.05).
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Fig.32 Celebrex modulates tumor differentiation and ameliorates Doxil resi tance.
(A) Cumulative data show % of tumor volume reduction of SN25ASP tumors treated al n
with Doxil, Celebrex (ns) or Doxil plus Celebrex treatment (**p=0,0041). Bars refer t mean
values ±SEM. (B) E-Cadherin staining on SN25ASP tumors treated alone with 5 mg/kg r
Celebrex. Ecadherin is strongly re-expressed by SN25ASP tumors after elebrex treatment.
(left panels original magnification xl 00) (right panels original magnification x200).
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4.4 THE RELEVANCE TO HUMAN BREAST CANCER
OF SN25A/SN25ASP TUMOR MODELS
Dr. Tagliabue at the Istituto Nazionale Tumori identified a peculiar
extracellular matrix (ECM gene signature (ECM3» in breast carcinomas featuring
prognostic significance only in grade III undifferentiated tumor. The prominent gene of
the ECM3 signature is SPARC that, together with LAMA4, COLIAt and COLSA2,
consistently identifies the ECM3 signature by qRT-PCR. Multivariate analysis
indicated no independent prognostic value for ECM3, but the interaction between
ECM3 and grade resulted strongly and significantly associated with hazard ratio (HR)
of relapse (HR=5.35, p=O.OOl)in untreated breast carcinoma patients. The }IR relative
to ECM3 was markedly different in grade I-II (HR=O.6, p=O.08) compared with grade
III tumors (HR=2.S, p=O.038), indicating that ECM3 prognostic significance depends
on the tumor differentiation status. In agreement, the probability to develop metastases
in a 10-year follow-up was 10% for ECM3 differentiated tumors (grade I-II) and 55%
for the grade III ECM3. Moreover, the analysis of two data sets ofneo-adjuvant treated
patients revealed that, among the grade III tumors, pathological complete response was
reached by 15% of ECM3 versus 85% of non-ECM3 tumors. Comparison between
ECM3 and all others revealed no difference in response to chemotherapy in
differentiated (grade I-II) tumors. The data on the biology of SPARe presented here
might in part explain why the same signature is detected in well-differentiated and
undifferentiated tumors but with a different outcome. These data in fact support the
possibility that, in well-differentiated tumors, SPARC might drive stroma deposition,
whereas in grade III tumors it might contribute to the EMT phenotype and
chemoresistance. Accordingly, in grade III tumors the ECM3 signature defines the
subgroup that undergoes EMT. If SPARe regulation of EMT occurs through MDSCs
recruitment and eOX-2 activation, correlative human data should be found comparing
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ECM3 with MO tum r . In llab ration v ith Dr. Tripodo from the University of
Palermo, 1 ha anal z d infiltr ti n b immature myeloid cells (in human identified
by the marker 0 ) and th ir -2 production in ECM3 versus non-ECM3 tumors.
We found that M grad III tum r , in k ping the (differential) SPARC expression
d n incr a d infiltration by COX-2+ immune cells (Fig.
33). By contra t, n n- M" tumor how d OX-2 expression only by tumor cells.
Finally, G P ( pr ion Profil anal is) showed that ECM3 tumors are
enriched for gen r lat d to m el id c 11, whereas non-ECM3 tumors had a signature
associated with T-c II Fig. 34).
SPARC CD33 COX·2
Fig.33 SPARC expre ion correlates with COX-2 activity of CD33+ infiltrating myeloid
cells in ECM3 tumor.
ECMO tumors SP RC i \ idel distributed in tumor (a) and is associated to a reduced
number of CD33+ infiltrating m eloid cell (b) COX-2 is expressed by tumor cells. ECM3
tumors are characterized for a strongl PARC expression (d) present an high number of
infiltrating CD33+ m eloid cell (e) that pecificall expressed Cox-2 (1).
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Fig. 34 Gene set enrichment analysis (GSEA) in two datasets.
ECM3 is represented by up-regulation ofTGF {3 pathways, and membrane integrins wherea
non-ECM3 is characterized by overexpression of proliferation genes. Among grade III non-
ECM3 tumors are enriched for genes representative ofNK, T and B cells, and involved in cell
cycle progression, while EMT, hypoxia genes and genes representative of MD C cell w r
significantly up-modulated in ECM3 tumors.
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5.DISCUSSION
In this thesis, I have shown that SPARC is involved in the dynamics linking the
tumor microenvironment with drug resistance. SPARC expression in tumor cells
promoted EMT and was associated with a reduced response to chemotherapy. By
altering the balance between G-CSF and GM-CSF in favor of GM-CSF, SPARC
affected MDSC expansion and functionality. MDSCs were responsible for the EMT in
vivo phenotype because EMT in vivo could be reduced by bisphosphonates, a class of
drug that we have previously been shown capable of interfering with MDSC expansion
49. I have also proposed a mechanism for such a regulation and developed a rationale
for the use of COX-2 inhibitors or amino-bisphosphonates in combination with
conventional chemotherapy to treat a specific subset of breast cancer patients.
Tagliabue and colleagues analyzed the expression of extracellular matrix (ECM) genes
in breast carcinomas and identified four different profiles (ECMI, 2, 3 and 4) IS6.
Among them they found that the peculiar signature "ECM3" had prognostic
significance only in grade III tumors. The prominent gene of this signature was
SPARe, together with LAMA4, COLIAt and COL5A2. Multivariate analysis
indicated that the interaction between ECM3 and grade was strongly and significantly
associated with hazard ratio (HR) of relapse (HR=5.35, p=O.OOl) in untreated breast
carcinoma patients. The HR relative to ECM3 was markedly lower in grade I-II
(HR=O.6, p=O.08) compared with grade III tumors (HR=2.5, p=O.038), indicating that
ECM3 prognostic value varies according to the tumor differentiation status. In
addition, the comparison between grade III and grade I-II ECM3 showed that
undifferentiated grade III tumors are also less responsive to therapy. This raises the
query of how the same gene signature could predict a worse prognosis in grade III than
in grade I-II tumors. Triulzi and colleagues showed that ECM3 is a robust cluster that
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characterizes breast carcinomas with EMT features and increased metastatic potential
only in undifferentiated grade III tumors, but the authors did not provide any biological
mechanism to explain why the same ECM signature, enriched for SPARC, had
prognostic significance only in grade III tumors but not in grade I tumors. Data from
this PhD thesis might help explain at least in part this apparent inconsistency. Our
initial finding in SPARC biology 157 was that in well-differentiated adenocarcinoma,
where both tumor and stromal cells express SPARC (N2C, N3D and NIG cell lines),
SPARC was required to correctly assemble collagen type IV fibers in the stroma.
These tumors expressed SPARC at higher levels but were indolent tumors, unable to
promote metastasis formation 138 and were responsive to chemotherapy (N2C cell
linelDoxorubicin; Sangaletti S. unpublished). By contrast, in our SN25ASP model that
mimics the human basal type (among which are ECM3G3), a higher SPARC
expression than in the parental counterpart was associated with metastasis and
resistance to therapy. Thus, although SPARC was expressed by adenocarcinomas and
metastatic tumors its role was different and dependent on the tumor differentiation
status. In well-differentiated tumors, SPARC controlled stroma deposition 138, whereas
in grade III tumors, SPARC contributed to the EMT phenotype. In the
SN2SSPIN3DSPARC murine model, SPARC expression promoted a mesenchymal
phenotype and tumor immunosuppression. This could be in line with the more general
concept that mesenchymal cells might promote immunosuppression. Accordingly, cell
therapy with mesenchymal stromal cells (MSC) has emerged as a promising tolerance-
inducing strategy, as MSC are potent modifiers of immune cells within the adaptive as
well as the innate arm of the immune system. Casiraghi F. et a1.have hypothesized that
MSC-cell therapy may be useful to promote kidney transplantation tolerance!";
Ghannan et a1.showed that mesenchymal stem cells are able to inhibit human th 17 cell
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differentiation and function, and induce a regulatory T cell phenotype 159 via IL-IO. I
found that SN25ASP tumor cells in vivo elicit the expression of the potent immune-
suppressive cytokine IL-IO while, in vitro, they are capable of converting the
phenotype of activated neutrophils into pro-tumor neutrophils. Our data seems to
suggest that, unlike epithelial cells, mesenchymal tumor cells may possess the
machinery, which is normally provided by accessory cells (i.e. mesenchymal stromal
cells), to either promote tumor progression (collagens and ECM proteins among
others) or immune-suppression (by re-directing myeloid cells functions) also
suggesting that immune-modulatory drugs might be beneficial for the treatment of
refractory ECM303 tumors. The analysis for the expression of CD33 (myeloid cells)
and of COX-2 in human ECMOvs ECM3 tumors highlighted the increased presence of
COX-2+ infiltrating cells in ECM3 but not ECMO tumors that were associated with the
recruitment of CD33+ cells. Interestingly, the OEP (Gene Expression Profile analysis)
analysis of ECM3 vs ECMOtumors showed a different enrichment in genes related to
immune cells infiltration: ECM3 tumors were enriched in genes related to myeloid
cells (the csf-receptor) whereas ECMO tumors were enriched in genes related to T
cells. This data, together with data from murine models, suggested that a different
ECM might results in a different immune-microenvironment. This would confirm that
the ECM is not merely a scaffold but has a regulatory function. Accordingly,
Sangaletti et al have recently demonstrated that that loss of SPARC in secondary
lymphoid organs results in disruption of the ECM and defective collagen remodeling,
promoting B cell activation and lymphomagenesis. In our breast tumor model, SPARC
was shown to regulate MDSC function. We assumed that SPARC regulation occurs
through the activation of COX-2 that shifts the balance between O-CSF and OM-CSF,
together with a not well characterized, cell-to-cell mediated contact effect on myeloid
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cells. I hypothesized that this effect could be related to the capability of SPARC to
regulate TGFbeta signaling, similarly to what occurs in macrophages during fibrosis.
In this model, SPARC-deficiency renders macrophages unable to modulate TGF-B
signaling and, as consequence, to dampen inflammation or reduce TNF production.
Stressing our hypothesis about the involvement of TGF-B signaling, we found that
NBPs reverted the phenotype of MDSC also by down-modulating TGF-B signaling in
these cells, which in turn determined a reduced NF-kb activation. The use ofNBPs as
anti-cancer drug is not new: NBPs have entered clinical practice in the treatment of
bone metastases from several neoplasms, including breast and prostate
adenocarcinoma, as an anti-resorptive therapy. At the same time, evidence has
accumulated of the direct anti-tumor effects of NBPs. NBPs were, for example, found
to down-regulate hTERT gene expression in breast tumor cells 160 and to promote
apoptosis. The possibility of a synergistic NBPs action with conventional drugs in the
context of a subtype of tumors has been recently proposed as a new strategy that fits
well with the approach of targeted therapies. Is is nonetheless necessary to consider
that prior the reversion of the EMT-phenotype caused by NBPs-treatment, SN25ASP
tumors showed an increased proliferation index (number of Ki-67+ cells). This
suggests that the increased sensitivity to Doxil treatment was probably related to the
increased incorporation of the DNA-intercalating agent by SN25ASP cells that, being
less mesenchymal and more epithelial, proliferate more in vivo. A major question that
remains open is why the injection of SN25ASP tumors in Spare-null mice was
sufficient to revert the EMT phenotype. Spare-null mice were initially used to prove
that SN25ASP mesenchymal phenotype was immune-mediated and particularly related
to immunosuppression. Accordingly, our group has extensively reported an increased-
Ml activation in the absence of SPARCI2t• It is likely that, in the total absence of
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SPARC, the myeloproliferative stimulation is not promoted by the tumor production of
GM-CSF, but is rather mediated by a BM or splenic stroma. These hematopoietic
organs are, on one hand, capable of amplifying the myeloproliferative response by
generating more myeloid cells 122 and, on the other hand, they may favor the
generation of activated, anti-tumor myeloid cells in a process similar to that recently
described in the context of Iymphomagenesis'?'. In the context of lymphomagenesis in
a Spare-null background, the myeloproliferative spur provided by Fas mutation causes
the generation of splenic neutrophils with high expression of genes related to class II
and co-stimulation molecules, and the IFN signature indicating that these neutrophils
were activated and primed toward immunogenic cells death. Taken together, these
results suggest that both the over-expression of SPARC in tumor cells and its absence
in host cells are capable of modulating the behavior of myeloid cells. so that the
modulation of myeloid cells function could be the possible off-target in all diseases or
tumors characterized by altered SPARC expression. Regarding tumors, this picture
could be further complicated by the different roles of SPARC enrichment in tumors
depending on their differentiation status. Data from this thesis suggest a new use of
Bisphosphonates or Cox-2 inhibitors that, impairing MDSC expansion from the bone
marrow, can be a component of drug combinations expected to be more effective in
treating grade III breast-TM patients.
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